<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3108234072
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIBINQO
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ABROCITINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3901.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Deutschland GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Deutschland GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QD11AH
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cibinqo contains the active substance abrocitinib. It belongs to a group of medicines called Janus kinase inhibitors, which help to reduce inflammation. It works by reducing the activity of an enzyme in the body called &lsquo;Janus kinase&rsquo;, which is involved in inflammation.</p><p>&nbsp;</p><p>Cibinqo is used to treat adults and adolescents 12&nbsp;years and older with moderate-to-severe atopic dermatitis, also known as atopic eczema. By reducing the activity of Janus kinase enzymes, Cibinqo lessens itching and inflammation of the skin. This in turn can reduce sleep disturbances and other consequences of atopic eczema such as anxiety or depression and improves overall quality of life.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Cibinqo </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to abrocitinib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a serious infection ongoing, including tuberculosis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast-feeding (see the &ldquo;pregnancy, contraception, breast‑feeding and fertility&rdquo; section).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before and during treatment with Cibinqo if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an infection or if you often get infections. Tell your doctor if you get symptoms such as fever, wounds, feeling more tired than usual or dental problems as these can be signs of infection.<strong> </strong>Cibinqo can reduce your body&rsquo;s ability to fight infections and may make an existing infection worse or increase the chance of you getting a new infection. If you have diabetes or are aged 65&nbsp;years or older you may have an increased chance of getting infections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have, or have had, tuberculosis or have been in close contact with someone with tuberculosis. Your doctor will test you for tuberculosis before starting Cibinqo and may retest during treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever had a herpes infection (shingles), because Cibinqo may allow it to come back. Tell your doctor if you get a painful skin rash with blisters as this can be a sign of shingles.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever had hepatitis B or hepatitis C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have recently had or plan to have a vaccination (immunisation) - this is because certain vaccines (live vaccines) are not recommended while using Cibinqo.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have previously had blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) or have an increased risk for developing this (for example: if you had recent major surgery, if you use hormonal contraceptives\hormonal replacement therapy, if a coagulation defect is identified in you or your close relatives). Your doctor will discuss with you if Cibinqo is appropriate for you. Tell your doctor if you get sudden shortness of breath or difficulty breathing, chest pain or pain in upper back, swelling of the leg or arm, leg pain or tenderness, or redness or discoloration in the leg or arm as these can be signs of blood clots in the veins.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have, or had heart problems because your doctor will discuss with you if Cibinqo is appropriate for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had cancer, smoke or have smoked in the past, because your doctor will discuss with you if Cibinqo is appropriate for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-melanoma skin cancer has been observed in patients taking Cibinqo. Your doctor may recommend that you have regular skin examinations while taking Cibinqo. If new skin lesions appear during or after therapy or if existing lesions change appearance, tell your doctor.</p><p><u>&nbsp;</u></p><p><u>Additional monitoring tests</u></p><p>Your doctor will carry out blood tests before and during Cibinqo treatment and may adjust your treatment if necessary.</p><p><strong>&nbsp;</strong></p><p><strong>Children </strong></p><p>This medicine is not approved for use in children below the age of 12&nbsp;years because the safety and benefits of Cibinqo are not yet established.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Cibinqo </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist before taking Cibinqo if you are taking some of the medicines to treat:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infections (such as fluconazole), depression (such as fluoxetine or fluvoxamine), stroke (such as ticlopidine), as they may increase the side effects of Cibinqo.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach acid reflux (such as antacids, famotidine or omeprazole), as they may reduce the amount of Cibinqo in your blood.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression (such as citalopram, clobazam or escitalopram), as Cibinqo may increase their effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neurofibromatosis type I (such as selumetinib), as Cibinqo may increase its effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure (such as digoxin) or stroke (such as dabigatran), as Cibinqo may increase their effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures (such a S-mephenytoin), as Cibinqo may increase its effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke (such as clopidogrel), as Cibinqo may decrease its effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma, rheumatoid arthritis, or atopic dermatitis (such as biologic antibody therapies, medicines that control the body&rsquo;s immune response such as ciclosporin, other Janus kinase inhibitors, such as baricitinib, upadacitinib), as they may increase the risk of side effects.</p><p>&nbsp;</p><p>Your doctor can tell you to avoid using or stop taking Cibinqo if you are taking some of the medicines to treat:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tuberculosis (such as rifampicin), seizures or fits (such as phenytoin), prostate cancer (such as apalutamide, enzalutamide), or HIV infection (such as efavirenz), as these may reduce how well Cibinqo works.</p><p>&nbsp;</p><p>If any of the above apply to you or if you are not sure, talk to your doctor or pharmacist before taking Cibinqo.</p><p>&nbsp;</p><p><strong>Pregnancy, contraception, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><u>&nbsp;</u></p><p><u>Contraception in women</u></p><p>If you are a woman of childbearing potential, you should use an effective method of contraception during treatment with Cibinqo, and for at least one month after your last treatment dose. Your doctor can advise you on suitable methods of contraception.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Do not use Cibinqo if you are pregnant, think you may be pregnant or are planning to have a baby since it can harm the developing baby. Tell your doctor right away if you become pregnant or think you might have become pregnant during treatment.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>Do not use Cibinqo while breast-feeding as it is not known if this medicine passes into breast milk and affects the baby. You and your doctor should decide if you will breast-feed or use this medicine.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Cibinqo may cause temporary reduced fertility in woman of childbearing potential. This effect is reversible after stopping treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Cibinqo has no effect on the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Cibinqo contains lactose monohydrate and sodium</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>Patients aged 65&nbsp;years and older may be at increased risk of infections, heart attack and some types of cancer. Your doctor may decide that Cibinqo is not suitable for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Cibinqo is a tablet to be taken by mouth. It may be used with other eczema medicines that you apply on the skin or it may be used on its own.</p><p>&nbsp;</p><p>The recommended starting dose for adults and adolescents (12&nbsp;years to 17&nbsp;years of age) weighing at least 59&nbsp;kg, is 100&nbsp;mg or 200&nbsp;mg once a day as prescribed by your doctor. Your doctor may increase or decrease your dose depending on how well the medicine is working.</p><p>&nbsp;</p><p>Some patients need a lower starting dose and your doctor may give you 100&nbsp;mg once a day if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are 65&nbsp;years of age or older.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a certain medical history or medical condition.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are an adolescent (12&nbsp;years to 17&nbsp;years of age) weighing 25&nbsp;kg-58&nbsp;kg.</p><p>&nbsp;</p><p>If you have moderate-to-severe kidney problems, or if you are prescribed certain other medicines the starting dose can be either 50&nbsp;mg or 100&nbsp;mg once a day. You will get a starting dose based on your need and medical history or medical condition, therefore you should always take this medicine exactly as your doctor has told you.</p><p>&nbsp;</p><p>After starting treatment, your doctor can adjust the dose based on how well the medicine works and any side effect you get. If the medicine is working well, the dose may be reduced. Treatment may also be stopped temporarily or permanently if blood tests show low white blood cell or platelet counts.</p><p>&nbsp;</p><p>If you have taken Cibinqo for 24&nbsp;weeks and still show no improvement, your doctor may decide to permanently stop the treatment.</p><p>&nbsp;</p><p>You should swallow your tablet whole with water. Do not split, crush or chew the tablet before swallowing as it may change how much medicine that gets into your body.</p><p>&nbsp;</p><p>You can take the tablet either with or without food. If you feel sick (nausea) when taking this medicine, it may help to take it with food. To help you remember to take your medicine, it is suggested that you take it the same time every day.</p><p>&nbsp;</p><p><strong>If you take more Cibinqo than you should</strong></p><p>If you take more Cibinqo than you should, contact your doctor. You may get some of the side effects described in section 4.</p><p>&nbsp;</p><p><strong>If you forget to take Cibinqo </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose, take it as soon as you remember, unless your next dose is due in less than 12&nbsp;hours.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there is less than 12&nbsp;hours before your next dose, just skip the missed dose and take your next usual dose when it is due.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten tablet.</p><p>&nbsp;</p><p><strong>If you stop taking Cibinqo </strong></p><p>You should not stop taking Cibinqo without discussing this with your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>Talk to your doctor and get medical help straight away if you get any signs of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles (herpes zoster), a painful skin rash with blisters and fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the lungs, legs or pelvis with symptoms such as a painful swollen leg, chest pain or shortness of breath</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p><strong>&nbsp;</strong></p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cold sores and other types of herpes simplex infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acne</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in an enzyme called creatine phosphokinase, shown by blood test</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia (lung infection)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low platelet count shown by blood test</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low white blood cell count shown by blood test</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood fat (cholesterol) shown by blood test (see section 2 Warnings and precautions)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&ordm;C.</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton, bottle and blister foil after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is abrocitinib.</p><p>Each 50&nbsp;mg tablet contains 50&nbsp;mg of abrocitinib.</p><p>Each 100&nbsp;mg tablet contains 100&nbsp;mg of abrocitinib.</p><p>Each 200&nbsp;mg tablet contains 200&nbsp;mg of abrocitinib.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Tablet core: microcrystalline cellulose (E460i), calcium hydrogen phosphate anhydrous (E341ii), sodium starch glycolate, magnesium stearate (E470b).</p><p>Film‑coat: hypromellose (E464), titanium dioxide (E171), lactose monohydrate, macrogol (E1521), triacetin (E1518), iron red oxide (E172) (see section 2 Cibinqo contains lactose and sodium).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Cibinqo 50 mg tablets are pink, approximately 11 mm long and 5 mm wide oval tablets with “PFE” on one side and “ABR 50” on the other.
	
	Cibinqo 100 mg tablets are pink, approximately 9 mm in diameter round tablets with “PFE” on one side and “ABR 100” on the other.
	
	Cibinqo 200 mg tablets are pink, approximately 18 mm long and 8 mm wide oval tablets with “PFE” on one side and “ABR 200” on the other.
	
The 50 mg, 100 mg and 200 mg tablets are provided in high-density polyethylene (HDPE) bottles with polypropylene closure. Each bottle contains 30 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Limited</p><p>Ramsgate Road, Sandwich</p><p>Kent CT13 9NJ</p><p>UK</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>&nbsp;</p><p>Pfizer Manufacturing Deutschland GmbH</p><p>Freiburg, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ي</p><p dir="RTL">يحتوي سيبينكيو على المادة الفعالة أبروسيتينيب. وينتمي إلى مجموعة من الأدوية تُسمى مثبطات إنزيم كيناز الجانوز وهي تساعد على تخفيف الالتهاب. حيث تعمل عن طريق تقليل نشاط إنزيم في الجسم يسمى &quot;كيناز الجانوز&quot; وهو يساهم في الإصابة بالالتهاب.</p><p>&nbsp;</p><p dir="RTL">يُستخدم سيبينكيو لعلاج البالغين والمراهقين بعمر ١٢ عامًا فأكبر المصابين بالتهاب الجلد التأتبي المتوسط إلى الشديد، المعروف أيضًا بالإكزيما التأتبية. فعن طريق الحد من نشاط إنزيمات كيناز الجانوز، يقلل سيبينكيو من الحكة والتهاب الجلد. وهذا بدوره يمكن أن يقلل من اضطرابات النوم والتبعات الأخرى للإصابة بالإكزيما التأتبية مثل القلق أو الاكتئاب، ويحسن من نوعية الحياة بوجه عام.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;موانع استعمال سيبينكيو</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه أبروسيتينيب أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى خطيرة مستمرة، بما في ذلك السل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات شديدة في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية (انظري قسم &quot;الحمل والرضاعة&quot;).</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال سيبينكيو</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل وأثناء العلاج بسيبينكيو إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بعدوى أو إذا كنت تصاب بالعدوى كثيرًا. أخبر طبيبك إذا ظهرت عليك أعراض مثل الحمى، أو الجروح، أو الشعور بالتعب بمعدل أكثر من المعتاد، أو مشكلات في الأسنان لأن هذه يمكن أن تكون علامات على وجود عدوى. يمكن أن يقلل سيبينكيو من قدرة جسمك على محاربة العدوى، وقد يتسبب في تفاقم حالة العدوى التي تعاني منها أو يزيد من احتمالية إصابتك &nbsp;بعدوى جديدة. إذا كنت مصابًا بداء السكري أو كان عمرك ٦٥ عامًا أو أكثر، فقد تزيد احتمالية إصابتك بالعدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالسل حاليًا، أو سبق أن أُصبت به، أو خالطت عن قرب شخصًا مصابًا بالسل. سيُجري طبيبك اختبارًا للكشف عن إصابتك بالسل قبل بدء العلاج بسيبينكيو، وقد يعيد إجراء الاختبار أثناء تلقي العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبقت لك الإصابة بعدوى هربس (الحلأ النطاقي)، لأن تناول سيبينكيو قد يؤدي إلى الإصابة بها مجددًا. أخبر طبيبك إذا أُصبت بطفح جلدي مؤلم مع وجود بثور، فقد تكون هذه علامات على الإصابة بالحلأ النطاقي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبقت لك الإصابة بالتهاب الكبد الوبائي B أو التهاب الكبد الوبائي C.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد تلقيت لقاحًا مؤخرًا أو تخطط لتلقي لقاح (تطعيم) - وذلك لأنه لا يوصى بتلقي لقاحات معينة (اللقاحات الحية) أثناء استخدام سيبينكيو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبقت لك الإصابة بجلطات دموية في أوردة ساقيك (الخثار الوريدي العميق) أو رئتيك (الانصمام الرئوي) أو يزيد خطر إصابتك بذلك (على سبيل المثال: إذا خضعت لجراحة كبيرة مؤخرًا، إذا كنت تستخدم وسائل منع الحمل الهرمونية/العلاج بالهرمونات البديلة، إذا &nbsp;تأكد وجود خلل في تخثر الدم لديك أو لدى أقربائك المقربين). سيناقش طبيبك معك ما إذا كان سيبينكيو مناسبًا لك. أخبر طبيبك إذا أُصبت&nbsp; بضيق التنفس المفاجئ، أو صعوبة في التنفس، أو ألم في الصدر أو ألم في الجزء العلوي من الظهر، أو تورم في الساق أو الذراع، أو ألم في الساق أو إيلام، أو احمرار الساق أو الذراع أو تغير في اللون، فقد تكون هذه علامات على وجود جلطات دموية في الأوردة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك، أو سبق أن عانيت من مشكلات في القلب، لأن طبيبك سيناقش معك ما إذا كان سيبينكيو مناسبًا لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالسرطان أو سبقت لك الإصابة به أو إذا كنت تدخن أو كنت مدخنًا في الماضي لأن طبيبك سيناقش معك ما إذا كان سيبينكيو مناسبًا لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوحظت الإصابة بسرطان الجلد غير الميلانيني لدى المرضى الذين يتناولون سيبينكيو. قد يوصي طبيبك بإجراء فحوصات جلدية منتظمة في أثناء تناول سيبينكيو. إذا ظهرت آفات جلدية جديدة في أثناء العلاج أو بعده أو إذا تغير مظهر الآفات الموجودة، فأخبر طبيبك.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>اختبارات المراقبة الإضافية</u></p><p dir="RTL">سيُجري طبيبك فحوصات الدم قبل وأثناء العلاج بسيبينكيو، وقد يُعدِّل علاجك إذا لزم الأمر.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">هذا الدواء غير مصرح باستخدامه لدى الأطفال الذين تقل أعمارهم عن ١٢ عامًا لأن سلامة وفوائد سيبينكيو غير مُثبَّتة حتى الآن.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول حاليًا، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL">بوجه خاص، أخبر طبيبك أو الصيدلي قبل تناول سيبينكيو إذا كنت تتناول بعض الأدوية لمعالجة ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى الفطرية (مثل فلوكونازول)، الاكتئاب (مثل فلوكسيتين، أو فلوفوكسامين)، السكتة الدماغية (مثل تيكلوبيدين)، لأنها قد تُزيد من الأعراض الجانبية لسيبينكيو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاع حمض المعدة (مثل مضادات الحموضة، أو فاموتيدين، أو أوميبرازول)، لأنها قد تقلل من كمية سيبينكيو في دمك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب (مثل سيتالوبرام، أو كلوبازام، أو إسيتالوبرام)، لأن سيبينكيو قد يزيد من &nbsp;آثار هذه الأدوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الورم الليفي العصبي من النوع الأول (مثل سيلوميتينيب)، إذ قد يزيد سيبينكيو من آثاره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلب (مثل ديجوكسين) أو السكتة الدماغية (مثل دابيجاتران)، لأن سيبينكيو قد يُزيد من تأثيراتهما.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات (مثل إس ميفينيتوين)، ذلك أن سيبينكيو قد يزيد من آثاره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية (مثل كلوبيدوجريل)، ذلك أن سيبينكو قد يقلل من آثاره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو أو التهاب المفاصل الروماتويدي أو التهاب الجلد التأتبي (مثل العلاج بالأجسام المضادة الحيوية، الأدوية التي تتحكم في الاستجابة المناعية للجسم مثل سيكلوسبورين، مثبطات كيناز الجانوز الأخرى مثل باريسيتينب، أباداسيتنيب) لأنها قد تُزيد من خطر الإصابة بالأعراض الجانبية.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يخبرك طبيبك أو الصيدلي بتجنب استخدام سيبينكيو أو التوقف عن تناوله إذا كنت تتناول بعض الأدوية لمعالجة ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السل (مثل ريفامبيسين)، أو النوبات أو التشنجات (مثل فينيتوين)، أو سرطان البروستاتا (مثل أبالوتاميد، إنزالوتاميد)، أو عدوى فيروس نقص المناعة البشرية (HIV) (مثل إيفافيرينز)، لأنها قد تقلل من مدى كفاءة عمل سيبينكيو.</p><p>&nbsp;</p><p dir="RTL">إذا كان أي مما ورد أعلاه ينطبق عليك أو إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الصيدلي قبل تناول سيبينكيو.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تلقي هذا الدواء.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>منع الحمل لدى السيدات</u></p><p dir="RTL">إذا كنتِ سيدة قادرة على الإنجاب، ينبغي أن تستخدمي وسيلة فعالة لمنع الحمل أثناء فترة العلاج بسيبينكيو ولمدة شهر واحد على الأقل بعد تلقي آخر جرعة من العلاج. يمكن لطبيبكِ تقديم المشورة إليكِ بشأن وسائل منع الحمل المناسبة.</p><p>&nbsp;</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">لا تتناولي سيبينكيو إذا كنتِ حاملًا أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل نظرًا لأنه قد يسبب ضررًا للجنين النامي. أخبري طبيبك على الفور إذا أصبحتِ حاملًا أو كنتِ تعتقدين أنكِ ربما أصبحتِ حاملًا أثناء العلاج.</p><p>&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">لا تستخدمي سيبينكيو خلال فترة الرضاعة الطبيعية لأنه من غير المعروف ما إذا كان هذا الدواء يمر إلى لبن الثدي ويؤثر على الرضيع أم لا. ينبغي أن تقرري أنتِ وطبيبكِ ما إذا كنتِ سترضعين رضاعة طبيعية أم ستستخدمين هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">يمكن أن يتسبب سيبينكيو في تقليل الخصوبة بشكل مؤقت لدى السيدات القادرات على الإنجاب. هذا التأثير قابل للزوال بعد إيقاف العلاج.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير سيبينكيو على القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس لسيبينكيو أي تأثير على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات سيبينكيو</strong></p><p dir="RTL"><strong>يحتوي سيبينكيو على اللاكتوز أحادي الهيدرات والصوديوم</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك لا تستطيع تحمل بعض أنواع السكريات، فتواصل مع طبيبك قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من ۱ ملليمول من الصوديوم (٢٣ ملجم) لكل قرص، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; تقريبًا.</p><p dir="RTL">&nbsp;</p><p><u>كبار السن</u></p><p>قد يكون المرضى الذين تبلغ أعمارهم ٦٥ عامًا فأكبر أكثر عرضة للإصابة بالعدوى والنوبات القلبية وبعض أنواع السرطان. قد يقرر طبيبك أن سيبينكيو غير مناسب لك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. وارجع إلى طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي لك فعله.</p><p>&nbsp;</p><p dir="RTL">&nbsp;سيبينكيو هو قرص يؤخذ عبر الفم. ويمكن استخدامه مع أدوية الإكزيما الأخرى التي تضعها على الجلد أو يمكن استخدامه بمفرده.</p><p>&nbsp;</p><p dir="RTL">جرعة البدء الموصى بها للبالغين والمراهقين (من عمر ١٢ إلى ١٧ عامًا) الذين يبلغ وزنهم ٥٩ كلجم على الأقل هي ١٠٠ ملجم أو ۲٠٠ ملجم مرة واحدة يوميًا حسب إرشادات الطبيب. قد يزيد طبيبك جرعتك أو يخفضها بناءً على مدى فعالية الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;يحتاج بعض المرضى إلى تقليل جرعة البدء، ويمكن أن يُعطيك طبيبك جرعة قدرها ۱٠٠ ملجم مرة واحدة يوميًا إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عمرك ٦٥ عامًا فأكبر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك تاريخ طبي معين أو تعاني من حالة طبية معينة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مراهقًا (يتراوح عمرك بين ١٢ و١٧ عامًا) يبلغ وزنك من ٢٥ إلى ٥٨ كلجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من مشكلات كلوية متوسطة إلى شديدة من حيث الحدة، أو إذا وُصِفت لك أدوية أخرى معينة، يمكن أن تكون جرعة البدء إما ٥٠ ملجم أو ۱٠٠ ملجم مرة واحدة يوميًا. تُحدد جرعة البدء بناءً على احتياجاتك وتاريخك الطبي أو حالتك الطبية، لذلك ينبغي دائمًا أن تتناول هذا الدواء تمامًا كما أخبرك طبيبك.</p><p>&nbsp;</p><p dir="RTL">بعد بداية العلاج، يمكن لطبيبك أن يُعدل الجرعة بناءً على مدى كفاءة عمل الدواء وأي أعراض جانبية قد تصاب بها. ويمكن تقليل الجرعة إذا كان الدواء يعمل بكفاءة. قد يُوقف العلاج أيضًا بشكل مؤقت أو دائم إذا أظهرت فحوصات الدم انخفاضًا في تعداد خلايا الدم البيضاء أو الصفائح الدموية.</p><p>&nbsp;</p><p dir="RTL">إذا كنت ما زلت لا تُظهر أي تحسن بعد تناول سيبينكيو لمدة ٢٤ أسبوعًا، فقد يقرر طبيبك إيقاف العلاج بشكل دائم.</p><p>&nbsp;</p><p dir="RTL">ينبغي أن تبتلع القرص كاملًا بالماء. لا تقسم القرص، أو تسحقه، أو تمضغه قبل ابتلاعه لأن ذلك قد يغير كمية الدواء التي تدخل إلى جسمك.</p><p>&nbsp;</p><p dir="RTL">يمكنك تناول القرص مع الطعام أو دونه. إذا كنت تشعر بالرغبة في التقيؤ (الغثيان) عند تناول هذ الدواء، فقد يساعدك تناوله مع الطعام. ولمساعدتك على تذكُّر تناول دوائك، نقترح أن تتناوله في نفس الوقت كل يوم.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من سيبينكيو</strong></p><p dir="RTL">إذا تناولت كمية أكبر مما ينبغي من سيبينكيو، فتواصل مع طبيبك. قد تصاب ببعض الأعراض الجانبية الموضحة في القسم ٤.</p><p>&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة سيبينكيو</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فاتتك إحدى الجرعات، فتناولها بمجرد أن تتذكر ما لم يكن موعد جرعتك التالية بعد أقل من ١٢ ساعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت الفترة المتبقية حتى موعد جرعتك التالية تقل عن ١٢ ساعة، فتخط الجرعة الفائتة وتناول جرعتك التالية المعتادة في موعدها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مزدوجة لتعويض القرص الذي نسيته.</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول سيبينكيو</strong></p><p dir="RTL">ينبغي ألا تتوقف عن تناول سيبينكيو دون مناقشة ذلك مع طبيبك.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، غير أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL">تحدث إلى طبيبك و اطلب المساعدة الطبية على الفور إذا ظهرَت عليك أي علامات للإصابة بما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحلأ النطاقي (الهربس النطاقي)، وهو طفح جلدي مؤلم مع بثور وحمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الجلطات الدموية في الرئتين، أو الساقين، أو الحوض مع أعراض مثل التورم المؤلم في الساق، أو ألم الصدر، أو ضيق التنفس</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور برغبة في التقيؤ (الغثيان)</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح البرد و الأنواع الأخرى من عدوى فيروس الهربس البسيط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الإنزيم المعروف باسم فوسفوكيناز الكرياتين، وتظهر في فحص الدم</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي (عدوى الرئة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد الصفائح الدموية الذي يظهر في فحص الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم البيضاء الذي يظهر في فحص الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الدهون في الدم (الكولستيرول) الذي يظهر في فحص الدم (انظر القسم ٢ الاحتياطات عند استعمال سيبينكيو)</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عبر نظام الإبلاغ القومي. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p>&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL">مركز الاتصال الموحد: ۱۹۹۹۹</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp; </em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الكرتونية، والزجاجات، والرقائق المعدنية المُغلِّفة لشريط البليستر بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المادة الفعالة هي أبروسيتينيب.</p><p dir="RTL">يحتوي كل قرص ٥٠ ملجم على ٥٠ ملجم من أبروسيتينيب.</p><p dir="RTL">يحتوي كل قرص ١٠٠ ملجم على ١٠٠ ملجم من أبروسيتينيب.</p><p dir="RTL">يحتوي كل قرص ٢٠٠ ملجم على ٢٠٠ ملجم من أبروسيتينيب.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">لُبّ القرص: السليولوز البلوري المكروي (E460i)، فوسفات الكالسيوم الهيدروجيني اللامائي (E341ii)،جليكولات نشا الصوديوم، ستيارات المغنيسيوم (E470b).</p><p dir="RTL">طبقة الغلاف الرقيقة: هيبروميلوز (E464)، ثنائي أكسيد التيتانيوم (E171)، لاكتوز أحادي الهيدرات، ماكروجول (E1521)، ثلاثي الأسيتين (E1518)، أكسيد الحديد الأحمر (E172) (انظر القسم ٢ يحتوي سيبينكيو على اللاكتوز والصوديوم).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص سيبينكيو ٥٠ ملجم هي أقراص بيضاوية الشكل وردية اللون يبلغ طولها ١١ مم وعرضها ٥ مم تقريبًا، مطبوع على أحد جانبيها الرمز &quot;PFE&quot; وعلى الجانب الآخر &quot;ABR&nbsp;50&quot;.</p><p>&nbsp;</p><p dir="RTL">أقراص سيبينكيو ١٠٠ ملجم هي أقراص دائرية الشكل وردية اللون يبلغ قطرها ٩ مم تقريبًا، مطبوع على أحد جانبيها الرمز &quot;PFE&quot; وعلى الجانب الآخر &quot;ABR&nbsp;100&quot;.</p><p>&nbsp;</p><p dir="RTL">أقراص سيبينكيو ٢٠٠ ملجم هي أقراص بيضاوية الشكل وردية اللون يبلغ طولها ١٨ مم وعرضها ٨ مم تقريبًا، مطبوع على أحد جانبيها الرمز &quot;PFE&quot; وعلى الجانب الآخر &quot;ABR&nbsp;200&quot;.</p><p>&nbsp;</p><p dir="RTL">تتوفر الأقراص ذات جرعة ٥٠ ملجم و١٠٠ ملجم و٢٠٠ ملجم في عبوات مصنوعة من البولي إيثيلين عالي الكثافة (HDPE) مع غطاء من البولي بروبلين. تحتوي كل عبوة على ٣٠ قرصًا.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">فايزر المحدودة</p><p dir="RTL">المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;&rlm;الشركة الصانعة</strong></p><p dir="RTL">فايزر مانفاكشرينق جي ام بي انش ديتشلاند</p><p dir="RTL">فرييبرج، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cibinqo 50 mg film-coated tablets
Cibinqo 100 mg film-coated tablets
Cibinqo 200 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cibinqo 50 mg film-coated tablets

Each film-coated tablet contains 50 mg of abrocitinib.

Excipient with known effect
Each film-coated tablet contains 1.37 mg of lactose monohydrate.

Cibinqo 100 mg film-coated tablets

Each film-coated tablet contains 100 mg of abrocitinib.

Excipient with known effect
Each film-coated tablet contains 2.73 mg of lactose monohydrate. 

Cibinqo 200 mg film-coated tablets

Each film-coated tablet contains 200 mg of abrocitinib.

Excipient with known effect
Each film-coated tablet contains 5.46 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)

Cibinqo 50 mg film-coated tablets

Pink, approximately 11 mm long and 5 mm wide oval tablet debossed with “PFE” on one side and “ABR 50” on the other.

Cibinqo 100 mg film-coated tablets

Pink, approximately 9 mm in diameter round tablet debossed with “PFE” on one side and “ABR 100” on the other.

Cibinqo 200 mg film-coated tablets

Pink, approximately 18 mm long and 8 mm wide oval tablet debossed with “PFE” on one side and “ABR 200” on the other.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12&nbsp;years and older who are candidates for systemic therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and supervised by a healthcare professional experienced in the diagnosis and treatment of atopic dermatitis.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended starting dose is 100&nbsp;mg or 200&nbsp;mg once daily based on individual patient characteristics:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A starting dose of 100&nbsp;mg once daily is recommended for patients at higher risk of venous thromboembolism (VTE), major adverse cardiovascular event (MACE) and malignancy (see section 4.4). If the patient does not respond adequately to 100&nbsp;mg once daily, the dose can be increased to 200&nbsp;mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 200 mg once daily may be appropriate for patients who are not at higher risk of VTE, MACE and malignancy with high disease burden or for patients with an inadequate response to 100 mg once daily. Upon disease control, dose should be decreased to 100&nbsp;mg once daily. If disease control is not maintained after dose reduction, re-treatment with 200&nbsp;mg once daily can be considered. In adolescents (12&nbsp;years to 17&nbsp;years of age), weighing 25&nbsp;kg to &lt;&nbsp;59&nbsp;kg, a starting dose of 100&nbsp;mg once a day is recommended. If the patient does not respond adequately to 100&nbsp;mg once daily, the dose can be increased to 200&nbsp;mg once daily. In adolescents weighing at least 59&nbsp;kg, a starting dose of 100&nbsp;mg or 200&nbsp;mg once daily may be appropriate.</p><p>&nbsp;</p><p>The lowest effective dose for maintenance should be considered.</p><p>&nbsp;</p><p>Discontinuation of treatment should be considered in patients who show no evidence of therapeutic benefit after 24&nbsp;weeks.</p><p>&nbsp;</p><p>Cibinqo can be used with or without medicated topical therapies for atopic dermatitis.</p><p>&nbsp;</p><p><em>Laboratory monitoring</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:625px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1.&nbsp;&nbsp;&nbsp; Laboratory measures and monitoring guidance</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory measures</strong></p></td><td style="vertical-align:top"><p><strong>Monitoring guidance</strong></p></td><td style="vertical-align:top"><p><strong>Action</strong></p></td></tr><tr><td rowspan="4"><p>Complete blood count including Platelet Count, Absolute Lymphocyte Count (ALC), Absolute Neutrophil Count (ANC) and Haemoglobin (Hb)</p><p>&nbsp;</p></td><td rowspan="4"><p>Before treatment initiation, 4&nbsp;weeks after initiation and thereafter according to routine patient management.</p><p>&nbsp;</p></td><td><p>Platelets: Treatment should be discontinued if platelet counts are &lt;&nbsp;50&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup>.</p></td></tr><tr><td><p>ALC: Treatment should be interrupted if ALC is &lt;&nbsp;0.5&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> and may be restarted once ALC returns above this value. Treatment should be discontinued if confirmed.</p></td></tr><tr><td><p>ANC: Treatment should be interrupted if ANC is &lt;&nbsp;1 &times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> and may be restarted once ANC returns above this value.</p></td></tr><tr><td><p>Hb: Treatment should be interrupted if Hb is &lt;&nbsp;8<sup> </sup>g/dL and may be restarted once Hb returns above this value.</p></td></tr><tr><td><p>Lipid parameters</p></td><td><p>Before treatment initiation, 4&nbsp;weeks after initiation and thereafter according to the patient&rsquo;s risk for cardiovascular disease and clinical guidelines for hyperlipidaemia.</p></td><td><p>Patients should be monitored according to clinical guidelines for hyperlipidaemia.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Treatment initiation</em></p><p>Treatment should not be initiated in patients with a platelet count &lt;&nbsp;150&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup>, an absolute lymphocyte count (ALC) &lt;&nbsp;0.5&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup>, an absolute neutrophil count (ANC) &lt;&nbsp;1.2&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> or who have a haemoglobin value &lt;&nbsp;10&nbsp;g/dL (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Dose interruption</em></p><p>If a patient develops a serious infection, sepsis or opportunistic infection, dose interruption should be considered until the infection is controlled (see section 4.4).</p><p>&nbsp;</p><p>Interruption of dosing may be needed for management of laboratory abnormalities as described in Table 1.</p><p>&nbsp;</p><p><em>Missed doses</em></p><p>If a dose is missed, patients should be advised to take the dose as soon as possible unless it is less than 12&nbsp;hours before the next dose, in which case the patient should not take the missed dose. Thereafter, dosing should be resumed at the regular scheduled time.</p><p>&nbsp;</p><p><em>Interactions</em></p><p>In patients receiving dual strong inhibitors of CYP2C19 and moderate inhibitors of CYP2C9, or strong inhibitors of CYP2C19 alone (e.g. fluvoxamine, fluconazole, fluoxetine and ticlopidine), the recommended dose should be reduced by half to 100&nbsp;mg or 50&nbsp;mg once daily (see section 4.5).</p><p>&nbsp;</p><p>Treatment is not recommended concomitantly with moderate or strong inducers of CYP2C19/CYP2C9 enzymes (e.g. rifampicin, apalutamide, efavirenz, enzalutamide, phenytoin) (see section&nbsp;4.5).</p><p>&nbsp;</p><p>In patients receiving acid reducing agents (e.g. antacids, proton pump inhibitors and H2 receptor antagonists), 200&nbsp;mg once daily dose of abrocitinib should be considered (see section 4.5).</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em><em> </em></p><p>No dose adjustment is required in patients with mild renal impairment, i.e. estimated glomerular filtration rate (eGFR) of 60 to &lt;&nbsp;90&nbsp;mL/min.</p><p>&nbsp;</p><p>In patients with moderate (eGFR 30 to &lt;&nbsp;60&nbsp;mL/min) renal impairment, the recommended dose of abrocitinib should be reduced by half to 100&nbsp;mg or 50&nbsp;mg once daily (see section 5.2).</p><p>&nbsp;</p><p>In patients with severe (eGFR &lt;&nbsp;30&nbsp;mL/min) renal impairment, 50&nbsp;mg once daily is the recommended starting dose. The maximum daily dose is 100&nbsp;mg (see section 5.2).</p><p>&nbsp;</p><p>Abrocitinib has not been studied in patients with end-stage renal disease (ESRD) on renal replacement therapy.</p><p>&nbsp;</p><p><em>Hepatic impairment</em><em> </em></p><p>No dose adjustment is required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment. Abrocitinib is contraindicated to patients with severe (Child Pugh C) hepatic impairment (see section&nbsp;4.3).</p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>For patients 65&nbsp;years of age and older, the recommended dose is 100&nbsp;mg once daily (see section&nbsp;4.4).</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of Cibinqo in children under 12&nbsp;years of age have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>This medicinal product is to be taken orally once daily with or without food at approximately the same time each day.</p><p>&nbsp;</p><p>In patients who experience nausea, taking tablets with food may improve nausea.</p><p>&nbsp;</p><p>Tablets should be swallowed whole with water and should not be split, crushed or chewed because these methods have not been studied in clinical trials.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Active serious systemic infections, including tuberculosis (TB) (see section 4.4).
•	Severe hepatic impairment (see section 4.2).
•	Pregnancy and breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Abrocitinib should only be used if no suitable treatment alternatives are available in patients:</p><p>-65 years of age and older;</p><p>-patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers);</p><p>-patients with malignancy risk factors (e.g. current malignancy or history of malignancy)</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Infections/serious infections </u></p><p>&nbsp;</p><p>Serious infections have been reported in patients receiving abrocitinib. The most frequent serious infections in clinical studies were herpes simplex, herpes zoster and pneumonia (see section 4.8).<em> </em></p><p>&nbsp;</p><p>As there is a higher incidence of infections in the elderly and in the diabetic populations in general, caution should be used when treating the elderly and patients with diabetes. In patients 65&nbsp;years of age and older abrocitinib should only be used if no suitable treatment alternatives are available (see section 4.2).</p><p>&nbsp;</p><p>Treatment must not be initiated in patients with an active, serious systemic infection (see section 4.3).</p><p>&nbsp;</p><p>Risks and benefits of treatment prior to initiating abrocitinib should be considered for patients:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with chronic or recurrent infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have been exposed to TB</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with a history of a serious or an opportunistic infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have resided or travelled in areas of endemic TB or endemic mycoses; or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with underlying conditions that may predispose them to infection.</p><p>&nbsp;</p><p>Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with abrocitinib. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing and appropriate antimicrobial therapy should be initiated. The patient should be closely monitored and therapy should be temporarily interrupted if the patient is not responding to standard therapy.</p><p><em>&nbsp;</em></p><p><em>Tuberculosis</em></p><p>Tuberculosis was observed in clinical studies with abrocitinib. Patients should be screened for TB before starting treatment and yearly screening for patients in highly endemic areas for TB should be considered. Abrocitinib must not be given to patients with active TB (see section 4.3). For patients with a new diagnosis of latent TB or prior untreated latent TB, preventive therapy for latent TB should be started prior to initiation of treatment.</p><p>&nbsp;</p><p><em>Viral reactivation</em></p><p>Viral reactivation, including herpes virus reactivation (e.g. herpes zoster, herpes simplex), was reported in clinical studies (see section 4.8). The rate of herpes zoster infections was higher in patients who were treated with 200&nbsp;mg, 65&nbsp;years of age and older, with a medical history of herpes zoster, with a confirmed ALC &lt;&nbsp;1&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> prior to the event and patients with severe atopic dermatitis at baseline (see section 4.8). If a patient develops herpes zoster, temporary interruption of treatment should be considered until the episode resolves.</p><p>&nbsp;</p><p>Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy and during therapy. Patients with evidence of active hepatitis B or hepatitis C (positive hepatitis C&nbsp;PCR) infection were excluded from clinical studies (see section 5.2). Patients who were hepatitis B surface antigen negative, hepatitis B core antibody positive, and hepatitis B surface antibody positive had testing for hepatitis B virus (HBV) DNA. Patients who had HBV DNA above the lower limit of quantification (LLQ) were excluded. Patients who had HBV DNA negative or below LLQ could initiate treatment; such patients had HBV DNA monitored. If HBV DNA is detected, a liver specialist should be consulted.</p><p>&nbsp;</p><p><u>Vaccination</u></p><p>&nbsp;</p><p>No data are available on the response to vaccination in patients receiving abrocitinib. Use of live, attenuated vaccines should be avoided during or immediately prior to treatment. Prior to initiating treatment with this medicinal product, it is recommended that patients be brought up to date with all immunisations, including prophylactic herpes zoster vaccinations, in agreement with current immunisation guidelines.</p><p>&nbsp;</p><p><u>Venous thromboembolism (VTE)</u></p><p>&nbsp;</p><p>Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving abrocitinib (see section 4.8).</p><p>&nbsp;</p><p>In a large randomized active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50&nbsp;years and older with at least one additional cardiovascular risk factor, a dose dependent higher rate of VTE including deep venous thrombosis (DVT) and pulmonary embolism (PE) was observed with tofacitinib compared to TNF inhibitors.</p><p>&nbsp;</p><p>A higher rate of VTE was observed with abrocitinib 200&nbsp;mg compared to abrocitinib 100&nbsp;mg.</p><p>&nbsp;</p><p>In patients with cardiovascular or malignancy risk factors (see also section 4.4 &ldquo;Major adverse cardiovascular events (MACE)&rdquo; and &ldquo;Malignancy&rdquo;) abrocitinib should only be used if no suitable treatment alternatives are available.</p><p>&nbsp;</p><p>In patients with known VTE risk factors other than cardiovascular or malignancy risk factors, abrocitinib should be used with caution. VTE risk factors other than cardiovascular or malignancy risk factors include previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, inherited coagulation disorder.</p><p>&nbsp;</p><p>Patients should be re-evaluated periodically during abrocitinib treatment to assess for changes in VTE risk.</p><p>&nbsp;</p><p>Promptly evaluate patients with signs and symptoms of VTE and discontinue abrocitinib in patients with suspected VTE, regardless of dose.</p><p>&nbsp;</p><p><u>Major adverse cardiovascular events (MACE)</u></p><p><u>&nbsp;</u></p><p>Events of MACE have been observed in patients taking abrocitinib.</p><p><u>&nbsp;</u></p><p>In a large randomized active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50&nbsp;years and older with at least one additional cardiovascular risk factor, a higher rate of major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors.</p><p>&nbsp;</p><p>Therefore, in patients 65&nbsp;years of age and older, patients who are current or past long-time smokers, and patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors, abrocitinib should only be used if no suitable treatment alternatives are available.</p><p><u>&nbsp;</u></p><p><u>Malignancy (excluding non-melanoma skin cancer [NMSC])</u></p><p>&nbsp;</p><p>Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including abrocitinib.</p><p>&nbsp;</p><p>In a large randomized active controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50&nbsp;years and older with at least one additional cardiovascular risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma and non-melanoma skin cancer (NMSC) was observed with tofacitinib compared to TNF inhibitors.</p><p>&nbsp;</p><p>A higher rate of malignancies (excluding non-melanoma skin cancer, NMSC) was observed with abrocitinib 200&nbsp;mg compared to abrocitinib 100&nbsp;mg.</p><p>&nbsp;</p><p>In patients 65&nbsp;years of age and older, patients who are current or past long-time smokers, or with other malignancy risk factors (e.g. current malignancy or history of malignancy), abrocitinib should only be used if no suitable treatment alternatives are available.</p><p>&nbsp;</p><p><u>Non-melanoma skin cancer</u></p><p>&nbsp;</p><p>NMSCs have been reported in patients receiving abrocitinib. Periodic skin examination is recommended for all patients, particularly those who are at increased risk for skin cancer.</p><p><u>&nbsp;</u></p><p><u>Haematologic abnormalities</u></p><p>&nbsp;</p><p>Confirmed ALC &lt;&nbsp;0.5&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> and platelet count &lt;&nbsp;50&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> were observed in less than 0.5% of patients in clinical studies (see section 4.8). Treatment with abrocitinib should not be initiated in patients with a platelet count &lt;&nbsp;150&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup>, an ALC &lt;&nbsp;0.5&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup>, an ANC &lt;&nbsp;1.2&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> or who have a haemoglobin value &lt;&nbsp;10&nbsp;g/dL (see section&nbsp;4.2). Complete blood count should be monitored 4&nbsp;weeks after initiation of therapy and thereafter according to routine patient management (see Table&nbsp;1).</p><p>&nbsp;</p><p><u>Lipids</u></p><p>&nbsp;</p><p>Dose‑dependent increases in blood lipid parameters were reported in patients treated with abrocitinib compared to placebo (see section 4.8). Lipid parameters should be assessed approximately 4&nbsp;weeks following initiation of therapy and thereafter according to the patient&rsquo;s risk for cardiovascular disease (see Table&nbsp;1). The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined. Patients with abnormal lipid parameters should be further monitored and managed according to clinical guidelines, due to the known cardiovascular risks associated with hyperlipidaemia.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>The safety profile observed in elderly patients was similar to that of the adult population with the following exceptions: a higher proportion of patients 65&nbsp;years of age and older discontinued from clinical studies and were more likely to have serious adverse reactions compared to younger patients; patients 65&nbsp;years and older were more likely to develop low platelet and ALC values; the incidence rate of herpes zoster in patients 65&nbsp;years of age and older was higher than that of younger patients (see section&nbsp;4.8). There are limited data in patients above 75&nbsp;years of age.</p><p><u>&nbsp;</u></p><p><u>Use in patients 65&nbsp;years of age and older</u></p><p>Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients 65&nbsp;years of age and older, as observed in a large randomised study of tofacitinib (another JAK inhibitor), abrocitinib should only be used in these patients if no suitable treatment alternatives are available.</p><p><u>&nbsp;</u></p><p><u>Immunosuppressive conditions or medicinal products</u></p><p><u>&nbsp;</u></p><p>Patients with immunodeficiency disorders or a first-degree relative with a hereditary immunodeficiency were excluded from clinical studies and no information on these patients is available.</p><p>&nbsp;</p><p>Combination with biologic immunomodulators, potent immunosuppressants such as ciclosporin or other Janus kinase (JAK) inhibitors has not been studied. Their concomitant use with abrocitinib is not recommended as a risk of additive immunosuppression cannot be excluded.</p><p>&nbsp;</p><p><u>Excipients</u></p><p><em>&nbsp;</em></p><p><em>Lactose monohydrate</em></p><p>Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicinal product.</p><p><em>&nbsp;</em></p><p><em>Sodium </em></p><p>This medicinal product contains less than 1&nbsp;mmol&nbsp;sodium&nbsp;(23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Potential for other medicines to affect pharmacokinetics of abrocitinib</u></p><p>&nbsp;</p><p>Abrocitinib is metabolised predominantly by CYP2C19 and CYP2C9 enzymes, and to a lesser extent by CYP3A4 and CYP2B6 enzymes, and its active metabolites are renally excreted and are substrates of the organic anion transporter 3 (OAT3). Therefore, exposures of abrocitinib and/or its active metabolites may be affected by medicinal products that inhibit or induce these enzymes and transporter. Dose adjustments, as appropriate, are outlined in<em> </em>section 4.2.</p><p>&nbsp;</p><p><u>Co‑administration with CYP2C19/CYP2C9 inhibitors</u></p><p>&nbsp;</p><p>When 100&nbsp;mg abrocitinib was administered concomitantly with fluvoxamine (a strong CYP2C19 and moderate CYP3A inhibitor) or fluconazole (a strong CYP2C19, moderate CYP2C9 and CYP3A inhibitor), the extent of exposure of abrocitinib active moiety (see section 5.2) increased by 91% and 155%, respectively, compared with administration alone (see section 4.2).</p><p>&nbsp;</p><p><u>Co‑administration with CYP2C19/CYP2C9 inducers</u></p><p>&nbsp;</p><p>Administration of 200&nbsp;mg abrocitinib after multiple doses with rifampicin, a strong inducer of CYP enzymes, resulted in reduction of abrocitinib active moiety exposures by approximately 56% (see section 4.2).</p><p>&nbsp;</p><p><u>Co‑administration with OAT3 inhibitors</u></p><p>&nbsp;</p><p>When abrocitinib 200&nbsp;mg was administered concomitantly with probenecid, an OAT3 inhibitor, abrocitinib active moiety exposures increased by approximately 66%. This is not clinically significant, and a dose adjustment is not needed.</p><p>&nbsp;</p><p><u>Co-administration with products which increase gastric pH</u></p><p>&nbsp;</p><p>When abrocitinib 200&nbsp;mg was administered concomitantly with famotidine 40&nbsp;mg, an H2-receptor antagonist, abrocitinib active moiety exposures decreased by approximately 35%. The effect of elevating gastric pH with antacids, or proton pump inhibitors (omeprazole) on the pharmacokinetics of abrocitinib has not been studied and may be similar to that seen with famotidine. The higher 200 mg daily dose should be considered for patients treated concomitantly with products which increase gastric pH, as they may reduce the efficacy of abrocitinib.</p><p>&nbsp;</p><p><u>Potential for abrocitinib</u><u> </u><u>to affect pharmacokinetics of other medicinal products</u></p><p>&nbsp;</p><p>No clinically significant effects of abrocitinib were observed in interaction studies with oral contraceptives (e.g. ethinyl oestradiol/levonorgestrel).</p><p>&nbsp;</p><p><em>In vitro</em>, abrocitinib is an inhibitor of P glycoprotein (P-gp). Co-administration of dabigatran etexilate (a P-gp substrate), with a single dose of abrocitinib 200&nbsp;mg increased dabigatran AUC<sub>inf </sub>and C<sub>max</sub> by approximately 53% and 40%, respectively, compared with administration alone. Caution should be exercised for concomitant use of abrocitinib with dabigatran. The effect of abrocitinib on the pharmacokinetics of other P-gp substrates has not been evaluated. Caution should be exercised as the levels of P-gp substrates with a narrow therapeutic index, such as digoxin, may increase.</p><p>&nbsp;</p><p><em>In vitro</em>, abrocitinib is an inhibitor of CYP2C19 enzyme. Co-administration of abrocitinib 200&nbsp;mg once daily with omeprazole 10&nbsp;mg single dose increased the AUC<sub>inf </sub>and C<sub>max </sub>of omeprazole by approximately 189% and 134%, respectively, indicating that abrocitinib is a moderate inhibitor of CYP2C19 enzyme. Caution should be exercised when using abrocitinib concomitantly with narrow therapeutic index medicines that are primarily metabolised by CYP2C19 enzyme (e.g.&nbsp;S‑mephenytoin and clopidogrel). Dose adjustment may be required for other medicines primarily metabolised by CYP2C19 enzyme in accordance with their product information (e.g. citalopram, clobazam, escitalopram and selumetinib).</p><p>&nbsp;</p><p>Co-administration of abrocitinib 200 mg once daily with caffeine 100 mg single dose increased the AUC<sub>inf </sub>of caffeine by 40% with lack of effect on C<sub>max</sub>, suggesting that abrocitinib is a mild inhibitor of CYP1A2 enzyme. No general dose adjustment can be recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of reproductive potential should be advised to use effective contraception during treatment and for 1&nbsp;month following the final dose of Cibinqo. Pregnancy planning and prevention for females of reproductive potential should be encouraged.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data on the use of abrocitinib in pregnant women. Studies in animals have shown reproductive toxicity. Abrocitinib has been shown to cause embryo-foetal lethality in pregnant rats and rabbits, skeletal variations in the foetuses of pregnant rats and rabbits, and to affect parturition and peri/postnatal development in rats (see section&nbsp;5.3). Cibinqo is contraindicated during pregnancy (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>There are no data on the presence of abrocitinib in human milk, the effects on the breast‑fed infant, or the effects on milk production. Abrocitinib was secreted in milk of lactating rats<em>.</em> A risk to newborns/infants cannot be excluded and Cibinqo is contraindicated during breast‑feeding (see section&nbsp;4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Based on the findings in rats, oral administration of Cibinqo may result in temporary reduced fertility in females of reproductive potential. The effects on female rat fertility were reversible 1 month after cessation of abrocitinib oral administration (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cibinqo has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most commonly reported adverse reactions are nausea (15.1%), headache (7.9%), acne (4.8%), herpes simplex (4.2%), blood creatine phosphokinase increased (3.8%), vomiting (3.5%), dizziness (3.4%) and abdominal pain upper (2.2%). The most frequent serious adverse reactions are infections (0.3%) (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>A total of 3&nbsp;848&nbsp;patients were treated with abrocitinib in clinical studies in atopic dermatitis. Among them 3&nbsp;050&nbsp;patients (representing 5&nbsp;166&nbsp;patient-years of exposure) were integrated for safety analysis. The integrated safety analysis included 1&nbsp;997&nbsp;patients receiving a constant dose of abrocitinib 200&nbsp;mg and 1&nbsp;053&nbsp;patients receiving a constant dose of 100&nbsp;mg. There were 2&nbsp;013&nbsp;patients with at least 48 weeks of exposure. Five placebo‑controlled studies were integrated (703&nbsp;patients on 100&nbsp;mg once daily, 684&nbsp;patients on 200&nbsp;mg once daily and 438&nbsp;patients on placebo) to evaluate the safety of abrocitinib in comparison to placebo for up to 16&nbsp;weeks.</p><p>&nbsp;</p><p>Listed in Table 2 are adverse reactions observed in atopic dermatitis clinical studies presented by system organ class and frequency, using the following categories: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000); very rare (&lt;&nbsp;1/10&nbsp;000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:631px"><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 2.</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Herpes simplex<sup>a</sup></p><p>Herpes zoster<sup>b</sup></p></td><td style="vertical-align:top"><p>Pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Lymphopenia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipidaemia<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Venous thromboembolism<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Abdominal pain upper</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acne</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Creatine phosphokinase increased ˃&nbsp;5&nbsp;&times;&nbsp;ULN<sup>e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a.<sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Herpes simplex includes oral herpes, ophthalmic herpes simplex, genital herpes, and herpes dermatitis.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Herpes zoster includes ophthalmic herpes zoster.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp; Hyperlipidaemia includes dyslipidaemia and hypercholesterolaemia.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; Venous thromboembolism includes pulmonary embolism and deep vein thrombosis.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp; Includes changes detected during laboratory monitoring (see text below).</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Description of selected adverse reactions</u></p><p><em>&nbsp;</em></p><p><em>Infections</em></p><p>In placebo‑controlled studies, for up to 16&nbsp;weeks, infections have been reported in 27.4% of patients treated with placebo and in 34.9% and 34.8% of patients treated with abrocitinib 100&nbsp;mg and 200&nbsp;mg, respectively. Most infections were mild or moderate. The percentage of patients reporting infection‑related adverse reactions in the 200&nbsp;mg and 100&nbsp;mg groups compared to placebo were: herpes simplex (4.2% and 2.8% versus 1.4%), herpes zoster (1.2% and 0.6% versus 0%), pneumonia (0.1% and 0.1% versus 0%). Herpes simplex was more frequent in patients with a history of herpes simplex or eczema herpeticum. Most of the herpes zoster events involved a single dermatome and were non‑serious. Most opportunistic infections were cases of herpes zoster (0.70 per 100&nbsp;patient‑years in the abrocitinib 100&nbsp;mg group and 0.96 per 100&nbsp;patient-years in the abrocitinib 200&nbsp;mg group), most of which were non-serious multidermatomal cutaneous infections. Among all patients treated in clinical studies with consistent dosing regimens of either abrocitinib 100&nbsp;mg or 200&nbsp;mg, including the long-term extension study, the incidence rate of herpes zoster in patients treated with abrocitinib 200&nbsp;mg (4.36 per 100&nbsp;patient-years) was higher than that of patients treated with 100&nbsp;mg (2.61 per 100&nbsp;patient-years). Incidence rates for herpes zoster were also higher for patients 65&nbsp;years of age and older (HR 1.76), patients with a medical history of herpes zoster (HR 3.41), patients with severe atopic dermatitis at baseline (HR 1.17), and a confirmed ALC &lt;&nbsp;1.0&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> prior to the event of herpes zoster (HR 2.18) (see section&nbsp;4.4).</p><p><strong>&nbsp;</strong></p><p>In placebo‑controlled studies, for up to 16&nbsp;weeks, the rate of serious infections was 1.81 per 100&nbsp;patient-years in patients treated with placebo, 3.32 per 100&nbsp;patient-years in patients treated with 100&nbsp;mg, and 1.12 per 100&nbsp;patient-years in patients treated with 200&nbsp;mg. Among all patients treated in clinical studies with consistent dosing regimens of either abrocitinib 100&nbsp;mg or 200&nbsp;mg, including the long-term extension study, the rate of serious infections was 2.20 per 100&nbsp;patient-years treated with 100&nbsp;mg and 2.48 per 100&nbsp;patient-years treated with 200&nbsp;mg. The most commonly reported serious infections were herpes simplex, herpes zoster, and pneumonia (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Venous thromboembolism</em></p><p>Among all patients treated in clinical studies with consistent dosing regimens of either abrocitinib 100&nbsp;mg or 200&nbsp;mg, including the long‑term extension study, the rate of PE was 0.21 per 100&nbsp;patient‑years for 200&nbsp;mg and 0.05 per 100&nbsp;patient‑years for 100&nbsp;mg. The rate of DVT was 0.06 per 100&nbsp;patient-years in the 200&nbsp;mg group and 0.05 per 100&nbsp;patient‑years in the 100&nbsp;mg group (see section&nbsp;4.4).</p><p><em>&nbsp;</em></p><p><em>Thrombocytopenia</em></p><p>In placebo‑controlled studies, for up to 16&nbsp;weeks, treatment was associated with a dose‑related decrease in platelet count. Maximum effects on platelets were observed within 4&nbsp;weeks, after which the platelet count returned towards baseline despite continued therapy. Confirmed platelet counts of &lt;&nbsp;50&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> were reported in 0.1% of patients exposed to 200&nbsp;mg, and in 0&nbsp;patients treated with 100&nbsp;mg or placebo. Among all patients treated with clinical studies with consistent dosing regimens of either abrocitinib 100&nbsp;mg or 200&nbsp;mg, including the long‑term extension study, the rate of confirmed platelet counts of &lt;&nbsp;50&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> was 0.15 per 100&nbsp;patients-years for 200&nbsp;mg and 0 per 100&nbsp;patient‑years for 100&nbsp;mg, most occurring at Week&nbsp;4. Patients 65&nbsp;years of age and older had a higher rate of platelet counts &lt;&nbsp;75&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup>&nbsp;(see section 4.4).</p><p>&nbsp;</p><p><em>Lymphopenia</em></p><p>In placebo‑controlled studies, for up to 16&nbsp;weeks, confirmed ALC &lt;&nbsp;0.5&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> occurred in 0.3%&nbsp;of patients treated with 200&nbsp;mg and 0% of patients treated with 100&nbsp;mg or placebo. Both cases occurred in the first 4&nbsp;weeks of exposure. Among all patients treated in clinical studies with consistent dosing regimens of either abrocitinib 100&nbsp;mg or 200&nbsp;mg, including the long‑term extension, the rate of confirmed ALC &lt;&nbsp;0.5&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> was 0.34 per 100&nbsp;patient-years for 200&nbsp;mg and 0.05 per 100&nbsp;patient‑years for 100&nbsp;mg, the highest rate was observed in patients 65&nbsp;years of age and older (see section 4.4).</p><p>&nbsp;</p><p><em>Lipid elevations</em></p><p>In placebo‑controlled studies, for up to 16&nbsp;weeks, there was a dose‑related increase in low-density lipoprotein cholesterol (LDL-c), total cholesterol, and high-density lipoprotein cholesterol (HDL‑c) relative to placebo at Week&nbsp;4 which remained elevated through the final visit in the treatment period. There was no meaningful change in the LDL/HDL ratio in patients treated with abrocitinib relative to patients treated with placebo. Events related to hyperlipidaemia occurred in 0.4% of patients exposed to abrocitinib 100&nbsp;mg, 0.6% of&nbsp;patients exposed to 200&nbsp;mg and 0% of patients exposed to placebo (see section 4.4).</p><p>&nbsp;</p><p><em>Creatine phosphokinase elevations (CPK)</em></p><p>In placebo‑controlled studies, for up to 16&nbsp;weeks, significant increases in CPK values (&gt;&nbsp;5&nbsp;&times;&nbsp;ULN) occurred in 1.8% of patients treated with placebo, 1.8% of patients treated with 100&nbsp;mg and 3.8% of patients treated with 200&nbsp;mg of abrocitinib, respectively. Most elevations were transient and none led to discontinuation.</p><p><em>&nbsp;</em></p><p><em>Nausea</em></p><p>In placebo-controlled studies, for up to 16&nbsp;weeks, nausea was reported in 1.8% of patients treated with placebo and in 6.3% and 15.1% of patients treated with 100&nbsp;mg and 200&nbsp;mg, respectively. Discontinuation due to nausea occurred in 0.4% of patients treated with abrocitinib. Among patients with nausea, 63.5% of patients had onset of nausea in the first week of therapy. The median duration of nausea was 15&nbsp;days. Most of the cases were mild to moderate in severity.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>A total of 635&nbsp;adolescent patients (12 to less than 18&nbsp;years of age) were treated with abrocitinib in clinical studies in atopic dermatitis representing 1&nbsp;326.1 patient-years of exposure. The safety profile observed in adolescents in atopic dermatitis clinical studies was similar to that of the adult population.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cibinqo was administered in clinical studies up to a single oral dose of 800&nbsp;mg and 400&nbsp;mg daily for 28&nbsp;days. Adverse reactions were comparable to those seen at lower doses and no specific toxicities were identified. In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions (see section 4.8). Treatment should be symptomatic and supportive. There is no specific antidote for overdose with this medicinal product.</p><p>&nbsp;</p><p>Pharmacokinetics data up to and including a single oral dose of 800&nbsp;mg in healthy adult volunteers indicate that more than 90% of the administered dose is expected to be eliminated within 48&nbsp;hours.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other dermatological preparations, agents for dermatitis, excluding corticosteroids; ATC code: D11AH08</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Abrocitinib is a Janus kinase (JAK)1 inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of haematopoiesis and immune cell function. JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Inhibition of JAK1 modulates the signalling pathways by preventing the phosphorylation and activation of STATs.</p><p>&nbsp;</p><p>In biochemical assays, abrocitinib has selectivity for JAK1 over the other 3 JAK isoforms JAK2 (28‑fold), JAK3 (&gt;&nbsp;340-fold) and tyrosine kinase 2 (TYK2, 43-fold). In cellular settings, it preferentially inhibits cytokine-induced STAT phosphorylation by signalling pairs involving JAK1, and spares signalling by JAK2/JAK2, or JAK2/TYK2 pairs. The relevance of selective enzymatic inhibition of specific JAK enzymes to clinical effect is not currently known.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p><em>Clinical biomarkers</em></p><p>Treatment with abrocitinib was associated with dose-dependent reduction in serum biomarkers of inflammation in atopic dermatitis [interleukin-31 (IL‑31), interleukin-22 (IL-22), eosinophil count, and thymus and activation-regulated chemokine (TARC)], JAK1 signalling [natural killer (NK) cell count and interferon gamma-induced protein 10 (IP-10)] or both [high sensitivity C-reactive protein (hsCRP)]. These changes were reversible after treatment discontinuation.</p><p>&nbsp;</p><p>Mean absolute lymphocyte count increased by 2 weeks after starting treatment with abrocitinib and returned to baseline by Month 9 of treatment. Most patients maintained an ALC within the reference range. Treatment with abrocitinib was associated with a dose-related increase in B cell counts and a dose-related decrease in NK cell counts. The clinical significance of these changes in B&nbsp;cell and NK cell counts is unknown.</p><p>&nbsp;</p><p><em>Cardiac electrophysiology</em></p><p>The effect of abrocitinib on the QTc interval was examined in subjects who received a single supratherapeutic dose of abrocitinib 600&nbsp;mg in a placebo- and positive-controlled thorough QT study. A concentration-dependent QTc prolonging effect of abrocitinib was seen; the mean (90% confidence interval) for the increase in QTc interval was 6.0&nbsp;(4.52,&nbsp;7.49)&nbsp;msec, indicating the lack of a clinically relevant effect of abrocitinib on QTc interval at the dose tested.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy and safety of abrocitinib as monotherapy and in combination with background medicated topical therapies over 12-16 weeks were evaluated in 1&nbsp;616&nbsp;patients in 3 pivotal Phase 3 randomised, double-blind, placebo-controlled studies (MONO-1, MONO‑2, and COMPARE). In addition, the efficacy and safety of abrocitinib in monotherapy over 52&nbsp;weeks (with the option of rescue treatment in flaring patients) was evaluated in 1&nbsp;233 patients in a Phase 3 induction, randomised withdrawal, double-blind, placebo-controlled study (REGIMEN). The patients in these 4 studies were 12&nbsp;years of age and older with moderate-to-severe atopic dermatitis as defined by Investigator&rsquo;s Global Assessment (IGA) score &ge;&nbsp;3, Eczema Area and Severity Index (EASI) score &ge;&nbsp;16, BSA involvement &ge;&nbsp;10%, and Peak Pruritus Numerical Rating Scale (PP-NRS) &ge;&nbsp;4 at baseline prior to randomisation. Patients who had a prior inadequate response or for whom topical treatments were medically unadvisable, or who had received systemic therapies were eligible for inclusion. All patients who completed the parent studies were eligible to enrol into the long-term extension study EXTEND.</p><p><em>&nbsp;</em></p><p><em>Baseline characteristics</em></p><p>In the placebo-controlled studies (MONO-1, MONO-2, COMPARE) and the open-label induction, randomised withdrawal study (REGIMEN), across all treatment groups 41.4% to 51.1% were female, 59.3% to 77.8% were Caucasian, 15.0% to 33.0% were Asian and 4.1% to 8.3% were Black, and the mean age was 32.1 to 37.7 years. A total of 134&nbsp;patients 65&nbsp;years of age and older were enrolled in these studies. In these studies, 32.2% to 40.8% had a baseline IGA of 4 (severe atopic dermatitis), and 41.4% to 59.5% of patients had received prior systemic treatment for atopic dermatitis. The baseline mean EASI score ranged from 28.5 to 30.9, the baseline PP-NRS ranged from 7.0 to 7.3 and the baseline Dermatology Life Quality Index (DLQI) ranged from 14.4 to 16.0.</p><p><u>&nbsp;</u></p><p><em>Clinical response </em></p><p>&nbsp;</p><p><em><u>12-week monotherapy (MONO-1, MONO-2) and 16-week combination therapy (COMPARE) studies</u></em></p><p>A significantly larger proportion of patients achieved both primary endpoints IGA 0 or 1 and/or EASI‑75 with 100&nbsp;mg or 200&nbsp;mg once daily abrocitinib compared with placebo at Week&nbsp;12 or Week&nbsp;16 (see Table&nbsp;3 and Table 4).</p><p>&nbsp;</p><p>A significantly greater proportion of patients achieved at least a PP-NRS 4-point improvement with 100&nbsp;mg or 200&nbsp;mg once daily abrocitinib compared with placebo. This improvement was observed as early as Week&nbsp;2 and persisted through Week&nbsp;12 (Figure&nbsp;1).</p><p>&nbsp;</p><p>In the COMPARE study, superiority of abrocitinib 200&nbsp;mg compared with dupilumab at Week&nbsp;2 was demonstrated for the proportion of patients achieving at least a PP-NRS 4-point improvement with significantly higher itch responses seen as early as Day&nbsp;4 after the first dose.</p><p>&nbsp;</p><p>Treatment effects in subgroups (e.g. weight, age, sex, race and prior systemic&nbsp;immunosuppressant treatment) in MONO-1, MONO-2 and COMPARE were consistent with the results in the overall study population.</p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 3.&nbsp;&nbsp;&nbsp; Efficacy results of abrocitinib in monotherapy </strong><strong>at Week&nbsp;12</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>MONO-1<sup>d</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>MONO-2<sup>d</sup></strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week&nbsp;12</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Week&nbsp;12</strong></p></td><td>&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Abrocitinib monotherapy</strong></p></td><td rowspan="3" style="vertical-align:bottom"><p><strong>PBO</strong></p><p><strong>N=77</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Abrocitinib </strong><strong>monotherapy</strong></p></td><td rowspan="3" style="vertical-align:bottom"><p><strong>PBO</strong></p><p><strong>N=78</strong></p></td><td>&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>200&nbsp;mg QD</strong></p><p><strong>N=154</strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>100&nbsp;mg QD</strong></p><p><strong>N=156</strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>200&nbsp;mg QD</strong></p><p><strong>N=155</strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>100&nbsp;mg QD</strong></p><p><strong>N=158</strong></p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:bottom"><p><strong>% Responders (95% CI)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>IGA 0 or 1<sup>a</sup></p></td><td style="vertical-align:top"><p>43.8<sup>e</sup></p><p>(35.9, 51.7)</p></td><td style="vertical-align:top"><p>23.7<sup>e</sup></p><p>(17.0, 30.4)</p></td><td style="vertical-align:top"><p>7.9</p><p>(1.8, 14.0)</p></td><td style="vertical-align:top"><p>38.1<sup>e</sup></p><p>(30.4, 45.7)</p></td><td style="vertical-align:top"><p>28.4<sup>e</sup></p><p>(21.3, 35.5)</p></td><td style="vertical-align:top"><p>9.1</p><p>(2.7, 15.5)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>EASI-75<sup>b</sup></p></td><td style="vertical-align:top"><p>62.7<sup>e</sup></p><p>(55.1, 70.4)</p></td><td style="vertical-align:top"><p>39.7<sup>e</sup></p><p>(32.1, 47.4)</p></td><td style="vertical-align:top"><p>11.8</p><p>(4.6, 19.1)</p></td><td style="vertical-align:top"><p>61.0<sup>e</sup></p><p>(53.3, 68.7)</p></td><td style="vertical-align:top"><p>44.5<sup>e</sup></p><p>(36.7, 52.3)</p></td><td style="vertical-align:top"><p>10.4</p><p>(3.6, 17.2)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>PP-NRS4<sup>c</sup></p></td><td style="vertical-align:top"><p>57.2<sup>e</sup></p><p>(48.8, 65.6)</p></td><td style="vertical-align:top"><p>37.7<sup>e</sup></p><p>(29.2, 46.3)</p></td><td style="vertical-align:top"><p>15.3</p><p>(6.6, 24.0)</p></td><td style="vertical-align:top"><p>55.3<sup>e</sup></p><p>(47.2, 63.5)</p></td><td style="vertical-align:top"><p>45.2<sup>e</sup></p><p>(37.1, 53.3)</p></td><td style="vertical-align:top"><p>11.5</p><p>(4.1, 19.0)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:bottom"><p>Abbreviations: CI=confidence interval; EASI=Eczema Area and Severity Index; IGA=Investigator Global Assessment; N=number of patients randomised; PBO=placebo; PP-NRS=Peak Pruritus Numerical Rating Scale; QD=once daily.</p><p>a.&nbsp;&nbsp; IGA responders were patients with IGA score of clear (0) or almost clear (1) (on a 5‑point scale) and a reduction from baseline of &sup3;&nbsp;2&nbsp;points.</p><p>b.&nbsp;&nbsp; EASI-75 responders were patients with &ge;&nbsp;75% improvement in EASI from baseline.</p><p>c.&nbsp;&nbsp; PP-NRS4 responders were patients with &ge;&nbsp;4-point improvement in PP-NRS from baseline.</p><p>d.&nbsp;&nbsp; Abrocitinib used as monotherapy.</p><p>e.&nbsp;&nbsp; Statistically significant with adjustment for multiplicity versus placebo.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:603px"><thead><tr><td colspan="9" style="vertical-align:top"><p><strong>Table 4.&nbsp;&nbsp;&nbsp; Efficacy results of abrocitinib in combination with topical therapy </strong><strong>at Week&nbsp;12 and Week&nbsp;16</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="8" style="vertical-align:top"><p><strong>COMPARE<sup>d</sup> </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Week&nbsp;12</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td>&nbsp;</td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p><strong>Abrocitinib</strong><strong> </strong><strong>+ topicals</strong></p></td><td rowspan="3" style="vertical-align:top"><p><strong>PBO + topicals</strong></p><p><strong>N=131</strong></p></td><td rowspan="3" style="vertical-align:top"><p><strong>DUP + topicals</strong></p><p><strong>N=243</strong></p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p><strong>Abrocitinib</strong><strong> </strong><strong>+ topicals</strong></p></td><td rowspan="3" style="vertical-align:top"><p><strong>PBO + topicals</strong></p><p><strong>N=131</strong></p></td><td rowspan="3" style="vertical-align:top"><p><strong>DUP + topicals</strong></p><p><strong>N=243</strong></p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:bottom"><p><strong>200&nbsp;mg</strong></p><p><strong>QD</strong></p><p><strong>N=226</strong></p></td><td style="vertical-align:bottom"><p><strong>100&nbsp;mg</strong></p><p><strong>QD</strong></p><p><strong>N=238</strong></p></td><td style="vertical-align:bottom"><p><strong>200&nbsp;mg</strong></p><p><strong>QD</strong></p><p><strong>N=226</strong></p></td><td style="vertical-align:bottom"><p><strong>100&nbsp;mg</strong></p><p><strong>QD</strong></p><p><strong>N=238</strong></p></td><td>&nbsp;</td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="8" style="vertical-align:bottom"><p><strong>% Responders (95% CI)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>IGA 0 or 1<sup>a</sup></p></td><td style="vertical-align:top"><p>48.4<sup>e</sup></p><p>(41.8, 55.0)</p></td><td style="vertical-align:top"><p>36.6<sup>e</sup></p><p>(30.4, 42.8)</p></td><td style="vertical-align:top"><p>14.0</p><p>(8.0, 19.9)</p></td><td style="vertical-align:top"><p>36.5</p><p>(30.4, 42.6)</p></td><td style="vertical-align:top"><p>47.5<sup>e</sup></p><p>(40.9, 54.1)</p></td><td style="vertical-align:top"><p>34.8<sup>e</sup></p><p>(28.6, 40.9)</p></td><td style="vertical-align:top"><p>12.9</p><p>(7.0, 18.8)</p></td><td style="vertical-align:top"><p>38.8</p><p>(32.5, 45.1)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>EASI-75<sup>b</sup></p></td><td style="vertical-align:top"><p>70.3<sup>e</sup></p><p>(64.3, 76.4)</p></td><td style="vertical-align:top"><p>58.7<sup>e</sup></p><p>(52.4, 65.0)</p></td><td style="vertical-align:top"><p>27.1</p><p>(19.5, 34.8)</p></td><td style="vertical-align:top"><p>58.1</p><p>(51.9, 64.3)</p></td><td style="vertical-align:top"><p>71.0<sup>e</sup></p><p>(65.1, 77.0)</p></td><td style="vertical-align:top"><p>60.3<sup>e</sup></p><p>(53.9, 66.6)</p></td><td style="vertical-align:top"><p>30.6</p><p>(22.5, 38.8)</p></td><td style="vertical-align:top"><p>65.5</p><p>(59.4, 71.6)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>PP-NRS4<sup>c</sup></p></td><td style="vertical-align:top"><p>63.1</p><p>(56.7, 69.6)</p></td><td style="vertical-align:top"><p>47.5</p><p>(40.9, 54.1)</p></td><td style="vertical-align:top"><p>28.9</p><p>(20.8, 37.0)</p></td><td style="vertical-align:top"><p>54.5</p><p>(47.9, 61.0)</p></td><td style="vertical-align:top"><p>62.8</p><p>(55.6, 70.0)</p></td><td style="vertical-align:top"><p>47.0</p><p>(39.5, 54.6)</p></td><td style="vertical-align:top"><p>28.7</p><p>(19.6, 37.9)</p></td><td style="vertical-align:top"><p>57.1</p><p>(50.1, 64.2)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="9" style="vertical-align:bottom"><p>Abbreviations: CI=confidence interval; DUP=Dupilumab; EASI=Eczema Area and Severity Index; IGA=Investigator Global Assessment; N=number of patients randomised; PBO=placebo; PP-NRS=Peak Pruritus Numerical Rating Scale; QD=once daily.</p><p>a.&nbsp;&nbsp; IGA responders were patients with IGA score of clear (0) or almost clear (1) (on a 5‑point scale) and a reduction from baseline of &sup3;&nbsp;2&nbsp;points.</p><p>b.&nbsp;&nbsp; EASI-75 responders were patients with &ge;&nbsp;75% improvement in EASI from baseline.</p><p>c.&nbsp;&nbsp; PP-NRS4 responders were patients with &ge;&nbsp;4-point improvement in PP-NRS from baseline.</p><p>d.&nbsp;&nbsp; Abrocitinib used in combination with topical therapy.</p><p>e.&nbsp;&nbsp; Statistically significant with adjustment for multiplicity versus placebo.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>The proportion of patients who achieved PP-NRS4 over time in studies MONO-1, MONO-2 and COMPARE are shown in Figure 1.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Figure 1.</strong><strong>&nbsp;&nbsp; Proportion of patients who achieved PP-NRS4 over time in MONO-1, MONO-2 and COMPARE</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abbreviations: PP-NRS=Peak Pruritus Numerical Rating Scale; QD=once daily; Q2W=every 2 weeks.</p><p>PP-NRS4 responders were patients with &ge;&nbsp;4-point improvement in PP-NRS from baseline.</p><p>a.&nbsp;&nbsp; Abrocitinib used as monotherapy.</p><p>b.&nbsp;&nbsp; Abrocitinib used in combination with medicated topical therapy.</p><p>*&nbsp;&nbsp;&nbsp; Statistically significant with adjustment for multiplicity versus placebo.</p><p>**&nbsp; Statistically significant with adjustment for multiplicity versus dupilumab.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Health-related outcomes</em></p><p>In both monotherapy studies (MONO-1 and MONO-2) and in the combination therapy study (COMPARE), abrocitinib significantly improved patient-reported outcomes, including itch, sleep (SCORAD Sleep VAS), AD symptoms (POEM), quality of life (DLQI) and symptoms of anxiety and depression (HADS) that were uncorrected for multiplicity, at 12&nbsp;weeks compared to placebo (see Table 5).</p><p>&nbsp;</p><p><strong>Table 5.&nbsp;&nbsp;&nbsp; Patient-reported outcomes results of abrocitinib monotherapy and in combination with topical therapy at Week 12</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>Monotherapy</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Combination therapy </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>MONO-1</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>MONO-2</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>COMPARE</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>200&nbsp;mg</strong></p><p><strong>QD</strong></p></td><td style="vertical-align:top"><p><strong>100&nbsp;mg QD</strong></p></td><td style="vertical-align:top"><p><strong>PBO</strong></p></td><td style="vertical-align:top"><p><strong>200&nbsp;mg</strong></p><p><strong>QD</strong></p></td><td style="vertical-align:top"><p><strong>100&nbsp;mg QD</strong></p></td><td style="vertical-align:top"><p><strong>PBO</strong></p></td><td style="vertical-align:top"><p><strong>200&nbsp;mg QD + topicals</strong></p></td><td style="vertical-align:top"><p><strong>100&nbsp;mg QD + topicals</strong></p></td><td style="vertical-align:top"><p><strong>PBO + topicals</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>154</strong></p></td><td style="vertical-align:top"><p><strong>156</strong></p></td><td style="vertical-align:top"><p><strong>77</strong></p></td><td style="vertical-align:top"><p><strong>155</strong></p></td><td style="vertical-align:top"><p><strong>158</strong></p></td><td style="vertical-align:top"><p><strong>78</strong></p></td><td style="vertical-align:top"><p><strong>226</strong></p></td><td style="vertical-align:top"><p><strong>238</strong></p></td><td style="vertical-align:top"><p><strong>131</strong></p></td></tr><tr><td style="vertical-align:top"><p>SCORAD Sleep VAS, change from baseline</p><p>(95% CI)</p></td><td><p>-3.7*</p><p>(-4.2, -3.3)</p></td><td><p>-2.9*</p><p>(-3.4, -2.5)</p></td><td><p>-1.6</p><p>(-2.2, -1.0)</p></td><td><p>-3.8*</p><p>(-4.2, -3.4)</p></td><td><p>-3.0*</p><p>(-3.4, -2.6)</p></td><td><p>-2.1</p><p>(-2.7, -1.5)</p></td><td><p>-4.6*</p><p>(-4.9, -4.3)</p></td><td><p>-3.7*</p><p>(-4.0, -3.4)</p></td><td><p>-2.4</p><p>(-2.8, -2.0)</p></td></tr><tr><td style="vertical-align:top"><p>DLQI &ge;&nbsp;4-point improvement, % responders</p></td><td><p>72.6%*</p></td><td><p>67.2%*</p></td><td><p>43.6%</p></td><td><p>78.1%*</p></td><td><p>73.3%*</p></td><td><p>32.3%</p></td><td><p>86.4%*</p></td><td><p>74.7%*</p></td><td><p>56.5%</p></td></tr><tr><td style="vertical-align:top"><p>POEM, change from baseline</p><p>(95% CI)</p></td><td><p>-10.6*</p><p>(-11.8, -9.4)</p></td><td><p>-6.8*</p><p>(-8.0, -5.6)</p></td><td><p>-3.7</p><p>(-5.5, -1.9)</p></td><td><p>-11.0*</p><p>(-12.1, -9.8)</p></td><td><p>-8.7*</p><p>(-9.9, -7.5)</p></td><td><p>-3.6</p><p>(-5.3, -1.9)</p></td><td><p>-12.6*</p><p>(-13.6, -11.7)</p></td><td><p>-9.6*</p><p>(-10.5, -8.6)</p></td><td><p>-5.1</p><p>(-6.3, -3.9)</p></td></tr><tr><td style="vertical-align:top"><p>HADS Anxiety, change from baseline</p><p>(95% CI)</p></td><td><p>-2.1*</p><p>(-2.5, -1.6)</p></td><td><p>-1.6</p><p>(-2.0, -1.1)</p></td><td><p>-1.0</p><p>(-1.7, -0.4)</p></td><td><p>-1.7*</p><p>(-2.2, -1.2)</p></td><td><p>-1.6*</p><p>(-2.1, -1.1)</p></td><td><p>-0.6</p><p>(-1.3, 0.2)</p></td><td><p>-1.6*</p><p>(-2.0, -1.2)</p></td><td><p>-1.2*</p><p>(-1.5, -0.8)</p></td><td><p>-0.4</p><p>(-0.9, 0.1)</p></td></tr><tr><td style="vertical-align:top"><p>HADS Depression, change from baseline</p><p>(95% CI)</p></td><td><p>-1.8*</p><p>(-2.2, -1.4)</p></td><td><p>-1.4*</p><p>(-1.8, -0.9)</p></td><td><p>-0.2</p><p>(-0.8, 0.4)</p></td><td><p>-1.4*</p><p>(-1.8, -1.0)</p></td><td><p>-1.0*</p><p>(-1.5, -0.6)</p></td><td><p>0.3</p><p>(-0.3, 0.9)</p></td><td><p>-1.6*</p><p>(-1.9, -1.2)</p></td><td><p>-1.3*</p><p>(-1.6, -0.9)</p></td><td><p>-0.3</p><p>(-0.7, 0.2)</p></td></tr></tbody></table><p>CI=confidence interval; DLQI=Dermatology Life Quality Index; HADS=Hospital Anxiety and Depression Scale; N=number of patients randomised; PBO=placebo; POEM=Patient-Oriented Eczema Measure; QD=once daily; SCORAD=SCORing for AD; VAS=visual analog scale.</p><p>*Statistically significant without adjusting for multiplicity</p><p>&nbsp;</p><p><em>Open-label induction, randomised withdrawal study (REGIMEN)</em></p><p>A total of 1&nbsp;233&nbsp;patients received open-label abrocitinib 200&nbsp;mg once daily in the 12‑week run-in phase. Among these patients, 798&nbsp;patients (64.7%) met responder criteria (defined as achieving IGA [0 or 1] response and EASI‑75) and were randomised to placebo (267&nbsp;patients), abrocitinib 100&nbsp;mg once daily (265 patients) or abrocitinib 200&nbsp;mg once daily (266&nbsp;patients).</p><p>&nbsp;</p><p>Continuous treatment (200&nbsp;mg continuous) and induction-maintenance treatment (200&nbsp;mg for 12&nbsp;weeks followed by 100&nbsp;mg) prevented flare with 81.1% and 57.4% probability, respectively, versus 19.1% among patients who withdrew treatment (randomised to placebo) after 12&nbsp;weeks of induction. Three‑hundred fifty-one (351) patients including 16.2% of 200&nbsp;mg, 39.2% of 100&nbsp;mg and 76.4% of placebo patients received rescue medication of 200&nbsp;mg abrocitinib in combination with topical therapy.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Figure 2.&nbsp;&nbsp;&nbsp; Time to protocol-defined flare</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abrocitinib used as monotherapy.</p><p>Protocol-defined flare=A loss of at least 50% of the EASI response at Week&nbsp;12 and an IGA score of 2 or higher.</p><p>Multiplicity-controlled p &lt;&nbsp;0.0001 200&nbsp;mg versus placebo; 100&nbsp;mg versus placebo; 200&nbsp;mg versus 100&nbsp;mg.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Long-term efficacy</em></p><p>Eligible patients who completed the full treatment period of a qualifying parent study (e.g. MONO-1, MONO‑2, COMPARE, REGIMEN) were considered for enrolment in the long-term extension study EXTEND. In EXTEND, patients received abrocitinib with or without background medicated topical therapy. Patients who were previously randomised to medicinal product 100&nbsp;mg or 200&nbsp;mg once daily in parent studies continued the same dose in EXTEND as in the parent study. In EXTEND, patients received double-blind treatment until the parent study was completed, after which patients received single-blind treatment (treatment assignment disclosed to the investigators but not to the patients).</p><p>&nbsp;</p><p>Among patients who achieved response after 12&nbsp;weeks of treatment and entered EXTEND, the majority of patients maintained their response at Week&nbsp;96 of cumulative treatment for both doses of abrocitinib [64% and 72% for IGA (0 or 1) response, 87% and 90% for EASI-75, and 75% and 80% for PP-NRS4 with 100&nbsp;mg once daily and 200&nbsp;mg once daily, respectively].</p><p>&nbsp;</p><p>Among patients who did not achieve response after 12&nbsp;weeks of treatment and entered EXTEND, a proportion of patients achieved late-onset response by Week&nbsp;24 (from baseline) of continued treatment with abrocitinib [25% and 29% for IGA (0 or 1) response, and 50% and 57% for EASI-75 with 100&nbsp;mg once daily and 200&nbsp;mg once daily, respectively]. Patients who achieved partial response at Week&nbsp;12 were more likely than those with no response at Week&nbsp;12 to achieve treatment benefit at Week&nbsp;24.</p><p>&nbsp;</p><p>Patients who received dupilumab in the COMPARE study and subsequently entered EXTEND were randomised to either 100&nbsp;mg or 200&nbsp;mg of abrocitinib once daily upon entering EXTEND. Among non‑responders to dupilumab, a substantial proportion of patients achieved response 12&nbsp;weeks after switching to abrocitinib [34% and 47% for IGA&nbsp;(0&nbsp;or 1) response, and 68% and 80% for EASI-75 with 100&nbsp;mg once daily or 200&nbsp;mg once daily, respectively].</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with abrocitinib in one or more subsets of the paediatric population in the treatment of atopic dermatitis (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>The efficacy and safety of 12&nbsp;weeks of abrocitinib monotherapy were evaluated in 2&nbsp;Phase 3&nbsp;randomised, double‑blind, placebo-controlled studies (MONO-1, MONO‑2) which included 124&nbsp;patients who were 12 to less than 18&nbsp;years of age. The efficacy and safety of abrocitinib monotherapy over 52&nbsp;weeks (with the option of rescue treatment for flaring patients) were also evaluated in an open-label induction, randomised withdrawal study (REGIMEN), which included 246&nbsp;patients who were 12 to less than 18&nbsp;years of age. In these studies, the results in the adolescent subgroup were consistent with the results in the overall study population.</p><p>&nbsp;</p><p>The efficacy and safety of 12&nbsp;weeks of abrocitinib in combination with background medicated topical therapy were evaluated in the Phase&nbsp;3 randomised, double-blind, placebo-controlled study TEEN. The study included 287&nbsp;patients who were 12 to less than 18&nbsp;years of age with moderate-to-severe atopic dermatitis as defined by IGA score &ge;&nbsp;3, EASI score &ge;&nbsp;16, BSA involvement &ge;&nbsp;10%, and PP‑NRS &sup3;&nbsp;4 at the baseline visit prior to randomisation. Patients who had a prior inadequate response or who had received systemic therapy, were eligible for inclusion.</p><p>&nbsp;</p><p><em>Baseline characteristics</em></p><p>In TEEN, across all treatment groups 49.1% were female, 56.1% were Caucasian, 33.0% were Asian and 6.0% were Black patients. The median age was 15&nbsp;years and the proportion of patients with severe atopic dermatitis (IGA of 4) was 38.6%.</p><p>&nbsp;</p><p>Results of 12-week abrocitinib treatment in adolescents in pooled MONO-1 and MONO-2, and the TEEN study are shown in Table 6.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:97%"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 6.</strong><strong>&nbsp;&nbsp;&nbsp; </strong><strong>Adolescent efficacy results at Week 12 in pooled MONO-1 and MONO-2, and in TEEN</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Pooled MONO-1 and MONO-2</p></td><td colspan="3" style="vertical-align:top"><p>TEEN<sup>d</sup></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Abrocitinib</strong></p><p><strong>200 mg QD</strong></p></td><td style="vertical-align:top"><p><strong>Abrocitinib</strong></p><p><strong>100 mg QD</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Abrocitinib</strong></p><p><strong>200 mg QD</strong></p></td><td style="vertical-align:top"><p><strong>Abrocitinib</strong></p><p><strong>100 mg QD</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>IGA 0 or 1<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>93</p></td><td style="vertical-align:top"><p>89</p></td><td style="vertical-align:top"><p>94</p></td></tr><tr><td style="vertical-align:top"><p>%</p></td><td style="vertical-align:top"><p>31.3</p></td><td style="vertical-align:top"><p>22.0</p></td><td style="vertical-align:top"><p>8.7</p></td><td style="vertical-align:top"><p>46.2<sup>e</sup></p></td><td style="vertical-align:top"><p>41.6<sup>e</sup></p></td><td style="vertical-align:top"><p>24.5</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(18.1, 44.4)</p></td><td style="vertical-align:top"><p>(10.5, 33.5)</p></td><td style="vertical-align:top"><p>(0.0, 20.2)</p></td><td style="vertical-align:top"><p>(36.1, 56.4)</p></td><td style="vertical-align:top"><p>(31.3, 51.8)</p></td><td style="vertical-align:top"><p>(15.8, 33.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>EASI-75<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>93</p></td><td style="vertical-align:top"><p>89</p></td><td style="vertical-align:top"><p>94</p></td></tr><tr><td style="vertical-align:top"><p>%</p></td><td style="vertical-align:top"><p>56.3</p></td><td style="vertical-align:top"><p>44.0</p></td><td style="vertical-align:top"><p>8.7</p></td><td style="vertical-align:top"><p>72.0<sup>e</sup></p></td><td style="vertical-align:top"><p>68.5<sup>e</sup></p></td><td style="vertical-align:top"><p>41.5</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(42.2, 70.3)</p></td><td style="vertical-align:top"><p>(30.2, 57.8)</p></td><td style="vertical-align:top"><p>(0.0, 20.2)</p></td><td style="vertical-align:top"><p>(62.9, 81.2)</p></td><td style="vertical-align:top"><p>(58.9, 78.2)</p></td><td style="vertical-align:top"><p>(31.5, 51.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PP-NRS4<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>74</p></td><td style="vertical-align:top"><p>76</p></td><td style="vertical-align:top"><p>84</p></td></tr><tr><td style="vertical-align:top"><p>%</p></td><td style="vertical-align:top"><p>61.1</p></td><td style="vertical-align:top"><p>28.6</p></td><td style="vertical-align:top"><p>9.1</p></td><td style="vertical-align:top"><p>55.4<sup>e</sup></p></td><td style="vertical-align:top"><p>52.6</p></td><td style="vertical-align:top"><p>29.8</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(45.2, 77.0)</p></td><td style="vertical-align:top"><p>(14.9, 42.2)</p></td><td style="vertical-align:top"><p>(0.0, 21.1)</p></td><td style="vertical-align:top"><p>(44.1, 66.7)</p></td><td style="vertical-align:top"><p>(41.4, 63.9)</p></td><td style="vertical-align:top"><p>(20.0, 39.5)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviations: CI=confidence interval; EASI=Eczema Area and Severity Index; IGA=Investigator Global Assessment; N=number of evaluable patients; PP-NRS=Peak Pruritus Numerical Rating Scale; QD=once daily.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp; IGA responders were patients with IGA score of clear (0) or almost clear (1) (on a 5‑point scale) and a reduction from baseline of &sup3;&nbsp;2 points.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; EASI-75 responders were patients with &ge;&nbsp;75% improvement in EASI from baseline.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp; PP-NRS4 responders were patients with &ge;&nbsp;4-point improvement in PP-NRS from baseline.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; Abrocitinib used in combination with medicated topical therapy.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp; Statistically significant with adjustment for multiplicity versus placebo.</p></td></tr></tbody></table><p>&nbsp;</p><p>Among adolescent patients who achieved response after 12 weeks of treatment and entered long-term extension study EXTEND, the majority of patients maintained their response at Week 96 of cumulative treatment for both doses of abrocitinib [62% and 78% for IGA (0 or 1) response, 89% and 93% for EASI-75, and 77% and 76% for PP-NRS4 with 100&nbsp;mg and 200&nbsp;mg once daily, respectively].</p><p>&nbsp;</p><p>Among adolescent patients who did not achieve response after 12 weeks of treatment and entered EXTEND, a proportion of patients achieved late-onset response by Week 24 (from baseline) of continued treatment with both doses of abrocitinib [34% and 28% for IGA (0 or 1) response, and 41% and 55% for EASI-75 with 100&nbsp;mg and 200&nbsp;mg once daily, respectively].</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Abrocitinib is well-absorbed with over 91% extent of oral absorption and absolute oral bioavailability of approximately 60%. The oral absorption of abrocitinib is rapid and peak plasma concentrations are reached within 1&nbsp;hour. Steady‑state plasma concentrations of abrocitinib are achieved within 48&nbsp;hours after once daily administration. Both C<sub>max</sub> and AUC of abrocitinib increased dose proportionally up to 200&nbsp;mg. Co‑administration of abrocitinib with a high-fat meal had no clinically relevant effect on abrocitinib exposures (AUC and C<sub>max</sub> increased by approximately 26% and 29%, respectively, and T<sub>max</sub> was prolonged by 2&nbsp;hours). In clinical studies, abrocitinib was administered without regard to food (see section 4.2).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>After intravenous administration, the volume of distribution of abrocitinib is about 100 L. Approximately 64%, 37% and 29% of circulating abrocitinib and its active metabolites M1 and M2, respectively, are bound to plasma proteins. Abrocitinib and its active metabolites distribute equally between red blood cells and plasma.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>The <em>in vitro</em> metabolism of abrocitinib is mediated by multiple CYP enzymes, CYP2C19 (~53%), CYP2C9 (~30%), CYP3A4 (~11%) and CYP2B6 (~6%). In a human radiolabelled study, abrocitinib was the most prevalent circulating species, with mainly 3&nbsp;polar mono-hydroxylated metabolites identified as M1 (3‑hydroxypropyl), M2 (2-hydroxypropyl) and M4 (pyrrolidinone pyrimidine). At steady state, M2 and M4 are major metabolites and M1 is a minor metabolite. Of the 3 metabolites in circulation, M1 and M2 have similar JAK inhibitory profiles as abrocitinib, while M4 was pharmacologically inactive. The pharmacologic activity of abrocitinib is attributable to the unbound exposures of parent molecule (~60%) as well as M1 (~10%) and M2 (~30%) in systemic circulation. The sum of unbound exposures of abrocitinib, M1 and M2, each expressed in molar units and adjusted for relative potencies, is referred to as the abrocitinib active moiety.</p><p><em>&nbsp;</em></p><p><u>Elimination</u></p><p>&nbsp;</p><p>The elimination half-life of abrocitinib is about 5&nbsp;hours. Abrocitinib is eliminated primarily by metabolic clearance mechanisms, with less than 1% of the dose excreted in urine as unchanged active substance. The metabolites of abrocitinib, M1, M2 and M4 are excreted predominantly in urine, and are substrates of OAT3 transporter.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Body weight, gender, genotype, race and age</em></p><p>Body weight, gender, CYP2C19/2C9 genotype, race and age did not have a clinically meaningful effect on abrocitinib exposure (see section 4.2).</p><p>&nbsp;</p><p><em>Adolescents (&ge;&nbsp;12 to &lt;18&nbsp;years)</em></p><p>Based on population pharmacokinetic analysis, there was no clinically relevant difference in mean abrocitinib steady-state exposures in adolescent patients compared to adults at their typical body weights.</p><p>&nbsp;</p><p><em>Paediatric (&lt;&nbsp;12&nbsp;years)</em></p><p>Interaction studies have been performed in adults only. The pharmacokinetics of abrocitinib in children under 12&nbsp;years of age have not yet been established (see section 4.2).</p><p><em>&nbsp;</em></p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>In a renal impairment study, patients with severe (eGFR &lt;&nbsp;30&nbsp;mL/min) and moderate (eGFR&nbsp;30&nbsp;to&lt;&nbsp;60&nbsp;mL/min) renal impairment had approximately 191% and 110% increase in active moiety AUC<sub>inf</sub>, respectively, compared to patients with normal renal function (eGFR &ge;&nbsp;90&nbsp;mL/min) (see section 4.2<em>). </em>Pharmacokinetics of abrocitinib have not been determined in patients with mild renal impairment, however, based on the results observed in other groups, an increase of up to 70% in active moiety exposure is expected in patients with mild renal impairment (eGFR&nbsp;60&nbsp;to&lt;&nbsp;90&nbsp;mL/min). The increase of up to 70% is not clinically meaningful as the efficacy and safety of abrocitinib in atopic dermatitis patients with mild renal impairment (n=756) was comparable to the overall population in Phase&nbsp;2 and 3 clinical studies. The eGFR in individual patients was estimated using Modification of Diet in Renal Disease (MDRD) formula.</p><p>&nbsp;</p><p>Abrocitinib has not been studied in patients with ESRD on renal replacement therapy (see section 4.2). In Phase&nbsp;3 clinical studies, abrocitinib was not evaluated in patients with atopic dermatitis with baseline creatinine clearance values less than 40&nbsp;mL/min<em>.</em></p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Patients with mild (Child Pugh A) and moderate (Child Pugh B) hepatic impairment had approximately 4% decrease and 15% increase in active moiety AUC<sub>inf</sub>, respectively, compared to patients with normal hepatic function. These changes are not clinically significant, and no dose adjustment is required in patients with mild or moderate hepatic impairment (see section 4.2). In clinical studies, abrocitinib was not evaluated in patients with severe (Child Pugh C) hepatic impairment (see section 4.3), or in patients screened positive for active hepatitis B or hepatitis C (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General toxicity</u></p><p>&nbsp;</p><p>Decreased lymphocyte counts and decreased size and/or lymphoid cellularity of organs/tissues of the immune and haematopoietic systems were observed in nonclinical studies and were attributed to the pharmacological properties (JAK inhibition) of abrocitinib.</p><p>&nbsp;</p><p>In toxicity studies of up to 1&nbsp;month of abrocitinib dosing in rats at an age comparable to adolescent human age of &ge;&nbsp;12&nbsp;years, a microscopic bone dystrophy finding, considered transient and reversible, was noted, and exposure margins at which no bone finding was noted were 5.7 to 6.1&nbsp;times the human AUC at the maximum recommended human dose (MRHD) of 200&nbsp;mg. No bone findings were observed in rats at any dose in the 6‑month toxicity study (up to 25&nbsp;times the human AUC at the MRHD of 200&nbsp;mg) or in any of the toxicity studies in cynomolgus monkeys (comparable to human age of &ge;&nbsp;8&nbsp;years; up to 30&nbsp;times the human AUC at the MRHD of 200&nbsp;mg).</p><p><u>&nbsp;</u></p><p><u>Genotoxicity</u></p><p>&nbsp;</p><p>Abrocitinib was not mutagenic in the bacterial mutagenicity assay (Ames assay). It was not<em> aneugenic or clastogenic based on the results of the in vivo rat bone marrow micronucleus assay</em>.</p><p>&nbsp;</p><p><u>Carcinogenicity</u></p><p>&nbsp;</p><p>No evidence of tumorigenicity was observed in the 6-month Tg.rasH2 mice administered abrocitinib at oral doses up to 75&nbsp;mg/kg/day and 60&nbsp;mg/kg/day in female and male mice, respectively. In the 2‑year carcinogenicity study, higher incidence of benign thymoma was noted in female rats at the lowest dose tested. Thus, a lowest observed adverse effect level (LOAEL) is set in females at exposures equal to 0.6&nbsp;times the human AUC at the MRHD of 200&nbsp;mg. In males the no observed adverse effect level (NOAEL) was set at exposures equal to 13&nbsp;times the human AUC at the MRHD of 200&nbsp;mg. The human relevance of benign thymoma is unknown.</p><p>&nbsp;</p><p><u>Reproductive and developmental toxicity</u></p><p>&nbsp;</p><p>Abrocitinib had no effects on male fertility or spermatogenesis. Abrocitinib resulted in effects on female fertility (lower fertility index, corpora lutea, implantation sites and post-implantation loss), but no fertility effects were noted at exposures equal to 1.9&nbsp;times the human AUC at the MRHD of 200&nbsp;mg. The effects reversed 1&nbsp;month after cessation of treatment.</p><p>&nbsp;</p><p>No foetal malformations were observed in embryo-foetal development studies in rats or rabbits. In an embryo-foetal development study in pregnant rabbits, effects on embryo-foetal survival were noted at the lowest dose tested with exposures equal to 0.14 times the unbound human AUC at the MRHD of 200&nbsp;mg. Increased litter incidences of unossified hindlimb phalanges and tarsals and forelimb phalanges were observed with effects on forelimb phalanges noted at exposures equal to 0.14&nbsp;times the unbound human AUC at the MRHD of 200&nbsp;mg.</p><p>&nbsp;</p><p>In an embryo-foetal development study in pregnant rats, while increased embryo-foetal lethality was noted, none was observed at exposures equal to 10&nbsp;times the human AUC at the MRHD of 200&nbsp;mg. Increased incidence of skeletal variations of short 13<sup>th</sup> ribs, reduced ventral processes, thickened ribs, and unossified metatarsals were noted in the foetuses, but none were observed at exposures equal to 2.3&nbsp;times the human AUC at the MRHD of 200&nbsp;mg.</p><p>&nbsp;</p><p>In a pre- and postnatal development study in pregnant rats, dams had dystocia with prolonged parturition, offspring had lower body weights and lower postnatal survival. No maternal or developmental toxicity was observed in either dams or offspring at exposures equal to 2.3&nbsp;times the human AUC at the MRHD of 200&nbsp;mg.</p><p>&nbsp;</p><p>Administration of abrocitinib to juvenile rats beginning on postnatal Day&nbsp;10 (comparable to a 3‑month‑old human infant) resulted in adverse microscopic and macroscopic bone findings, including malrotated paws, fractures, and/or femoral head abnormalities at exposures&nbsp;&ge;&nbsp;0.8&nbsp;times the human AUC at the MRHD of 200&nbsp;mg. Administration of abrocitinib to juvenile rats beginning on postnatal Day&nbsp;21 and older (comparable to a 2‑year‑old human and older) was not associated with microscopic or macroscopic bone finding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>Microcrystalline cellulose (E460i)</p><p>Calcium hydrogen phosphate anhydrous (E341ii)</p><p>Sodium starch glycolate</p><p>Magnesium stearate (E470b)</p><p>&nbsp;</p><p><u>Film‑coat</u></p><p>&nbsp;</p><p>Hypromellose (E464)</p><p>Titanium dioxide (E171)</p><p>Lactose monohydrate</p><p>Macrogol (E1521)</p><p>Triacetin (E1518)</p><p>Iron red oxide (E172)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cibinqo 50&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p>High-density polyethylene (HDPE) bottle and polypropylene closure containing 30&nbsp;film-coated tablets.</p><p>&nbsp;</p><p><u>Cibinqo 100&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p>HDPE bottle and polypropylene closure containing 30&nbsp;film-coated tablets.</p><p>&nbsp;</p><p><u>Cibinqo 200&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p>HDPE bottle and polypropylene closure containing 30&nbsp;film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Autorisation Holder
Pfizer Limited
Ramsgate Road, Sandwich, Kent CT13 9NJ
UK

Manufacturer
Pfizer Manufacturing Deutschland GmbH
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>